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Abstract
Multiple sclerosis (MS) is a multi-faceted disease, and is believed to be caused by an
autoimmune response to myelin antigens in the central nervous system. Experimental
autoimmune encephalomyelitis (EAE), an animal model for MS, manifests itself in
various forms that parallel many aspects of MS. including the appearance of
symptoms, initiation events, and pathophysiology. The hallmark of any immune
response is the antigen-specific proliferation of immune cells, and during the
initiation events of EAE, prolil'erating CD4* T cells are the primery mediators of
disease. This thesis explores if targeting these proliferating cells with the anti-mitotic
compounds paclitaxel and peloruside A can delay or prevent the onset of EAE. thus
providing a novel therapeutic avenue for MS research.
The anti-cancer compound, paclitaxel, is an anti-mitotic drug that prevents
microtubule depolymerisation. Although paclitaxel has been used in the clinical
setting to treat cancer for over a decade, it has been determined that paclitaxel
stimulates murine toll-like receptor 4 (TLR4) complex, which is the major LPS
receptor. A novel microtubule-stabilising compound, peloruside, is currently subject
to intensive investigations due to its functional similarity to paclitaxel. The results
fiom this project found that peloruside and paclitaxel inhibited the proliferation of
mitogen-stimulilted splenocytes with ICso values of 83 nM and 30 nM, respectively,
but did not affect the viability of non-proliferating cells. In contrast to paclitaxel,
peloruside did not cause the TlR4-mediated production of the inflammatory
mediators. TNF-s, lL-12. and nitric oxide, when cultured with tFN-s stimulated
murine macrophages. Interestingly, when LPS was included with either paclitaxel or
vtnT trt6 |thnrtrDerTv ntr l,lfEt.LlNGToN
peloruside A, both drugs decreased theproduc-tion of TNF+ and nitric oxide from
macrophages, suggesting that microtubule-stabilising compounds may have anti-
inflamnntory effects.
To identify any imrnunomodifying effects of gnclitaxel in viva,paclitaxel was
adrninistered to mice that were irnmuni.sed with the ruryelin protein MOG in complete
Freundf s,adjuvant (CFA) to induce EAE. When Taxol wa.s administ€rd to mice for
5 consecutive days immediately fo.llowing CFAA4OG imrnunisation, the onset of
EAE was detayed'by approximately I week. Moreovet, the adrninisnation of
peloruside fol'lowing the sanre treatment regime also resulted in a similar delay of
d-isea;e onsel Taxol treaFnents, howe'vern lead ts significant mortality in irnm,unised,
but not unimmunisod mice. Interestinglh although Taxol is an'anti-mitotic d.rug the
prolif,eration of antigen-.specifis T cells was not inhibited in vivo by the Taxol
treatment. Ttle findings revealed in this thesis present an opportunity to pursue a new
avenue of, rese,arch for the therapeutic treatrnent of MS sufferer,s, and possibly other
inflamrnatory autoimmune disordem.
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Chapter 1: Introduction
1.1 General Introduction
Our knowledge of molecular biology and huntan diseases has expanded
exponentially over the past century with exciting new discoveries announced time
and time again. With the advent of new molecular techniques to identity novel drug
targets, biotechnology is ever increasingly delving into innovative ways to treat
difficult diseases. One such complex set of diseases includes those that fall under the
category of autoimmunity. Because autoimmune disorders. such as systematic lupus
erythematosus. rheumatoid arthritis. and multiple sclerosis, have no single known
cause of disease, there is little that can be done to prevent the initial induction with
the current technology. Treating autoimmunity after the onset of symptoms is
proving just as difficult. Although the cellular mechanisms of disease are being
elucidated, there is still no cure for autoimmunity. This situation, however, is bound
to change. New targets are coming to light, while old targets are being revisited with
novel approaches. The exciting field of biotechnology is in its infancy, and with all
of the technical knowledge of today, we are barely scratching the surface of what we
will see in the yeus to come.
This thesis is a condensed summarisation of a three-year project encompassing
multiple aspects of autoimmunity and the treatment thereof. The findings presented
herein may shed light on novel therapies for autoimmune diseases in general;
however, the primary focus of this research revolves around multiple sclerosis. It is
reasonable to say that, because of the multi-faceted nature of the immune system, a
cure for multiple sclerosis may come at a cost. For those that suffer with
t3
auroimfflunity, thi$ ooct may tre well wortli the risks. trt is the hope of this researcher
that this thesis can aid in the development of a ttrerapy ,sr cure f,or autOirnrnune
disordErs: that has minimal impact on other syfterns aside from the intended tar,get.
To uDderstand,the therapy, one mu$t understand the disease.
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I.2 Multiple Sclerosis
Multiple sclerosis (MS) is a disease caused by demyelination of nerves in the central
nervous system (CNS), often leaving affected individuals in a debilitated state.
Although the cause is still a mystery, it is believed to be an inflammatory
autoimmune disorder involving the destruction of myelin tissue by autoreactive
immune cells in the CNS. Myelin sheaths surround nerve fibers, protecting and
enhancing electrical impulses as they travel through the CNS. In MS, autoreactive
immune cells are believed to target myelin, causing lesions that can interfere with
nerve signal transduction in the CNS. The resulting inflammatory lesions can cause
irreversible damage to the myelin-producing oligodendrocytes. Despite recent
advances in our understanding of the disease, there are very few treatment options.
To date, there is no cure.
Cause of MS
Over the years, epidemiological and population studies have attempted to tease out a
specific cause of MS. Although there is still no single genetic or environmental
factor responsible lbr this disorder. there are associated genetic and environmental
risks with varying degrees of concordance that control the susceptibility to
developing MS. It is estimated that MS affects 2.5 million people worldwide, women
being 2 to 3 times more likely to develop MS than men. The predominance of MS in
women, as well as the temporary improvement of disease during pregnancy, provides
strong evidence of a hormonal link (Confavreux et at., 1998; Marrie, zO04). Several
studies have identified a sharp rise in the total number of regulatory T cells (T,"*)
during pregnancy (Somerset et a\..2004; Polanczyk et aL.,2005), which are
attributed to recovery from inflammation. The suppression of relapses and increased
l5
T,"* numbers during pregnancy may be attributed to the effects of high estradiol
and/or low progesterone (Sicotte et u\.,2002').
Hormonal diff'erences alone cannot explain the occurrence of MS since there is also a
clear genetic component. as shown by twin and family studies. If one identical twin
develops MS' the likelihood of the second twin getting MS increases compared to
non-identical twins (McFarland,lggz). tmmediate family members of MS patients
are also at an elevated risk for MS (Broadley et al.,2CfJl}; McFarland, 1992). The
exact genes responsible for the increased risk of MS are still being investigated;
however, a recent study reveals an association of MS incidence with variations in
HLA class I and II alleles, TCRe, crLA4, ICAMI, and SH2D2A, further supporting
underlying genetic involvement (Dyment et ul., Z0O4).
Although genetics has a role in MS, some people with many of the genetic risk.s do
not develop the disease. A large body of evidence exists that points to environmental
factors regulating disease induction. Because MS incidence increases the further one
lives from the equator, it has been postulated that decreased levels of UV light in the
wintertime, and the resulting decrease in vitamin D biosynthesis, is linked to MS
induction (Ponsonby et ul.,2oo2). vitamin D has many immunologicalfunctions
which supports the idea that deficiencies in vitamin D may increase the risk of
developing MS (cantorna, 2006; vanAmeron gen et at.,2004). one srudy found that
women who supplemented their diet with vitamin D had a significantly decreased
chance of developing MS (Mun ger et ul.,2oo4); however, other evidence suggests
that vitamin D has very little effect in MS parients already afflicted with MS
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(Wingerchuk et al',2005). Although vitamin D is frequently studied when pursuing
an environmental cause of MS, it is only one aspect of this complex clisease.
simple changes in protein structures, including amino acid modifications or
glycosylation, may initiate an autoimmune response. As an exampre, post-
translational modifications of myelin proteins have been implicated in MS (Beniac er
ttl.,2ooo: Mamula et al., 1999: Raijmakers et a1.,2005:van Boekel and van
Venrooij, 2003). One of the more popular theories is that there is a viral or bacterial
"trigger" that sets off a cascade of events, due to either molecular mimicry or
bystander activation, that ultimately leads to myelin-reactive immune cells entering
the CNS (Sospedra and Martin, 2005). An example of a post-infection neurological
disorder is Guillan-Barre syndrome 
- 
caused by molecular mimicry 
- 
whereby an
autoimmune response is initiated towards gangliosides because of their antigenic
similarities to antigens t'rom a primery infection. There is a strong concordance rate
between the development of MS and previous infection with Epstein-B1rr virus,
human herpes-virus 6, chlamidia pneumoniae, or other infectious agent$ (Martyn et
al., 1993: Moore et at.,2OO2; Sriram et at., l99g:respectively). In fact, one study
found that anti-Epstein-Barr virus antibodies were found in t 007o of MS patients (n
= 107) (Wandinger et at-,2Q00). Tarken together. these theories support the norion
that MS is a multi-faceted disease requiring several inpurs from both genetic and
environmental sources in order for the onset to occur.
Svmntoms of MS
The presentation of MS varies fiom case to case, but the most commonry
experienced symptoms include numbness and tingling in the hands and feet. limb
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weakness, and optic neuritis. As the disease progresses, the symproms may worsen to
include loss of manual dexterity, deterioration in mobility, impaired thinking, muscle
spasms' difficulty with speech and swallowing, and paralysis of extremities. Because
many of these symptoms are not specific to MS, the diagnosis of MS is difficult and
complex. There is no definitive test to confirm the diagnosis of MS; however, useful
information comes from patient history, MRI scans, spinal taps to determine tgG
levels, and serum antibody tests for myelin component reactivity.
There are four typical subsets of MS that are prevalent among patients: a) relapsing-
remitting, b) primary-progressive, c) secondary-progressive, and d) progressive-
relapsing (Fig' l.l )' The most common form of MS at rhe rime of original diagnosis
is relapsing-remitting (Fig. l. I a), accounting for as many as g5zc of all MS cases at
the time of original diagnosis. It is characterised by distinct periods of cNS
inflammation and worsening symptoms, tollowed by partial or complete recovery.
currently, there is no method to precrict a relapse. patients can be free tiom
exacerbation for months or years, and then suddenly experience a relapse lasting for
days or month.s. Relapsing-remitting MS frequently evolves into one of the other
forms with age.
Patients suffering from secondary-progressive MS (Fig. l.l c) typically show
symptoms similar to those with the relapsing_remitting forml however, the symptoms
of secondary-progressive patients tend to steadily worsen with or without disease
exacerbations. once the disease becomes mor€ progressive, minor recovery may or
may not occur. It is estimated that approximately 5ova of people who ultimately
r8
devetop relapsing=remittiqg MS develop this form of disease within the first decade
of initial diagnosis.
one of the less common Ms sub. typ.ea, p.rirmary-progressive (Fig. l. I b), is
charaeterised,b'y a steady worsening of symproms wi hemt dEftred pedods of relap*e.
Flateaus and tornporary improv,ements are not uncolnmon, and the r.ate of
de,generation may varyi This form otMS generally affects less than 10% of patients.
Even less cornmon, arsva of MS patients" is thepnogressive"relapsing fom of
disease (Fig' 1- l d). Frem the onset, these patients exhibit progressivg symptorns
with clearly defined inflammatory relapses. Minor recovery may follow these flare-
ups; but, unlike rela.psing-remitting MSi thers is a continuous progres-sion of disease
severify'. A more compretnensive,cgllEetion of MS information can be found on the
website fsrthe NationalMs society (www.nationalmssociety.org) in the usA.
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Etiolow of MS
Interestingly, the etiology of these different MS subtypes does not correlate with a
specific cellular cause. The lesions themselves show a considerable amount of
heterogeneity, with underlying cNS pathology ranging from oligodendropathy and
little inflammarion to highly inflamed lesions dominated by cDg* T cells and
macrophages (Lucchinetti et u\.,2000). Antibody involvement has atso been
attributed to the formation of cNS lesions (walsh et aI., 19g6:Baranzini et al.,
1999), and the highly elevated presence of antibodies in the cerebral spinal fluid is
common in MS patients (Kabat et al.,1950), which contributes to the diagnosis of
MS. Despite the variation of lesion presentation in later stages of disease, MS is still
generally considered a CD4"Th1-mediated disease, especially in the earlier stages
(Hellings et u1.,2002: Sospedra and Marrin, 2005; stinissen e/ al.,1997).This belief
is supported by the fact that CD4* T cells are, at least in part, necessary for the B cell
and CD8+T cell maturation. Moreover, the fbnction of two of the most promising
genetic susceptibility candidates, class ll-restricted HLA-DR and 
-De, is primnrily
associated with cD4* T cells. But, not all cD4* T cells are the same. It has been
shown that both MS patients and normal, healthy people have cD4* T cells that
respond to myelin proteins (Burns et ul., 1983), so auto-reactive T cells alone cannot
explain why some individuals get MS and others don't. Interestingly, MS patients
generally have a greater abundance of autoreactive T cells with l/104 or more T cells
being myelin-reactive (Muraro et al., z0o3: Hong er al., zffi4) indicating clonat r
cell expansion. Teasing out the overall picture of MS development gets complicated
considering ditficulties of obtaining pathological information from MS patients in a
non-invasive wav.
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Although a common and specific initiation event for MS has not been identified and
there is a variation of the general presentation of disease, as well as the heterogeneity
of lesions, there is enough evidence to piece together the pathophysiological
similarities that lead to the development of MS. As evidenced above, the early stages
of MS are primarily dominated by myelin reactive CD4* T cells of the Thr variety. In
conjunction with antigen presenting cells (Apc) displaying HLA-DR or 
-De, cD4*
T cells become activated in response to myelin proteins. These cells then expand. but
individuals may have variation in the downstream activation of other immune cell
activity, including mast cells, cD8* T cells, and B cells, which may explain the
phenotypic deviation and the presence of Th2-type cells in what is considered a Thr-
mediated disease. This basic model explains the initial events and inflammatory
relapse.s. but most MS patients present with relapsing and remitting phases.
A naturally suppressive subset of cD4* T cells exists that are also cD25* and
express FoxP3. These regulatory T cells (T,"*) ere involved in the resolution phase of
immune responses. In MS patients, however, overall rr"* numbers are generally
present at lower levels and the T,.g functions are not as suppressive (Viglietta et a/.,
2004)' suggesting that there might be an inability to effectively suppress a fl4re-up,
or an imptrired resolution of inflammation. studies on Tr"u involvement of
autoimmunity are in the early stages, but the evidence presented thus far gives a
strong indication that T,..*" may hold the key to ameliorating inflammation.
Nonetheless, cD4* T cells as a whole present an opportunity to develop drugs that
halt the initiation events of an inflammatory relapse, thus leading to an improvement
of MS symptoms. The CD4* T cell hypothesis is further supported by studies done in
22
the experimental autoimnrune encepharornyelitis (EAE) anirnal nrodel ol,MS
(Sospedra and Marrin. 200-5t.
23
1.3 Experimental Autoimmune Encephalomyelitis
There are written accounts and drawings from as far back as the Middle Ages
describing clezrly what we know now to be MS; however, the recognition of MS as a
specific disease 
- 
i.e., not "madness" 
- 
did not occur until the later decades of the
lgth century. The understanding of this disease grew at a very slow pace during the
first few decades of the 20th century. During this time, MS was believed to be virus-
induced. In 1935, Dr. Thomas Rivers of the Rockefeller Institute in New York City
injected virus-f'ree myelin into laboratory animals, ultimately causing an autoimmune
reaction to myelin (Rivers and Schwentker, 1935). The subsequent disease, now
referred to as EAE, had many of the characteristics of MS. The development of the
EAE animal model marked a tuming point for research into MS. To date, the EAE
animal model has provided valuable insight into MS pathophysiology, and it is still
the gold standard disease prototype. It is well known, however, that MS is not as
simple or straight forward as the EAE model (Sriram and Steiner, 2005: Steinman
and Zamvil, 2005), but the similarities have helped MS researchers around the world
develop an understanding of the human disease, as well as inflammatory
autoimmune diseases in general.
The EAE model has improved rnarkedly since the days of Dr. Rivers' initial
experiments. The model Dr. Rivers employed required 85 injections of rabbit brain
extracts over the course of a year to induce EAE in primates (Rivers and Schwentker,
1935). Today, with the help of complete Freund's adjuvant (CFA), the number of
injections of brain extract to bring about disease has been reduced to one. In addition,
variations in the EAE phenotype can be induced using different animals or different
24
myelin peptide fragments. Although each model has its own advantages and
disadvantages, they all have similarities to MS and its various sub-types.
Although the primate EAE model still exists. it is relatively inconvenient to do
studies considering the availability and ease of murine models of disease. In fact, the
murine models of EAE may be more suitable for the application of treatments to
human MS because of the similarities each bears to the various sub-types of MS. For
example, SJL mice with proteolipoprotein-induced EAE phenotypically display
several relapsing-remitting episodes of disease. One proposed mechanism for
relapsing EAE is believed to be epitope spreading (Miller et al.,2OO7), which has
also been postulated as a trigger for tlare-ups in human MS (Sospedra et a|.,2005).
Another example of EAE and MS similarities is the Lewis rat model when
immunised with spinal cord homogenate, which generally results in a single bout of
CNS inflammation followed by a partial or complete remission. Parallels have been
drawn between the Lewis rat model of EAE and primary-progressive MS. Some of
the newer animal models included in the EAE family involve transgenic mice,
including some that express T cells specific to myelin antigens. Specifically , the 2D2
transgenic EAE mouse model expres$es CD4* T cells with a specificity towards
MOGrs-s-s peptide (Bettelli et a|.,2003). Strikingly sirnilar to MS, the resulting CNS
inflammation may be spontaneous and is generally preceded by optic neuritis.
Various other EAE models have been utilised for their MS-like properties (Skundric,
2005), and more models are being developed that better represent the most current
understanding of MS etiology.
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When left non-immunised, most experimental animal strains do not typically develop
EAE. Disease can, however, be actively induced in normal healthy animals. The
EAE animal model is a result of initiating a CD4* T cell response towards a specific
myelin antigen. Myelin antigens commonly used for this purpose are myelin basic
protein (MBP), proteolipoprotein (PLP6c.r s r ), and myelin oligodendrocyte
glycoprotein (MOGls-ss). These antigens, in addition to complete Freund's adjuvant
(CFA), comprise the immunisation that causes actively induced EAE. EAE can also
be passively induced by transferring encephalitogenic T cells isolated from an animal
with EAE into a normal healthy animal of the same haplotype. Passive induction can
also be termed "adoptive transfer" and because this method by-passes the
activation/priming stage when naive T cells are activated, it is used to focus on the
later stages of the disease process involving CNS infiltration and nerve tissue
damage. The experiments described in this thesis will solely use active induction of
EAE in mice.
The EAE animal model used fbr the studies in this thesis is the C57BLi6 mouse. This
strain is commonly used, and, when EAE is induced. it is characterised by typical
disease onset two weeks post-immunisation (p.i.) fbllowed by a partial remission by
4 weeks p.i. There are many advantages to using this model, including high disease
incidence (80a/o-l00%o) and a consistent and progressive pattern of paralysis. Both
early-stage MS and the C57BL/6 model of EAE are considered CD4*Thr-mediated
diseases, thus providing a strong correlation between the work undertaken herein and
the translation of these results into possible outcomes for the treatment of MS.
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1.4 EAE Pathophysiology
Negative selection in the thymus during T cell development is believed to eliminate
the vast majority of irutoreactive T cells; however, there are autoreactive T cell
'nescapeesn'that have the potential to induce autoimmunity (Wekerle and Linington,
2006). The activities of these rogue T cells are generally kept under control during
normal immune function, and it takes the combination of auto-antigen with a strong
inflammatory adjuvant to trctivate the naive autoreactive T cells. Even after
activation of the naive cells, the cells must be able to tjnd their target organ/tissues to
cause disease.
The C57BL/6 model of actively induced EAE is brought about by immunising each
mouse subcutaneously with 50 eg of MOGrs-ss peptide emulsified in complete
Freund's itdjuvant (CFA); CFA contains incomplete Freund's adjuvant (IFA) and
heat-killed Mycobactet'ium tuherculosis (M.th.). Although MOG peptide is
quantitatively a minor component of myelin, it is still able to induce a powerfll
antigenic response in MOG-reactive T cells. In conjunction with the strong toll-like
receptor (TLR) agonist, M.tb., antigen-presenting cells (APCs) presenting MOG-
loaded MHC II molecules will activate the CD4* T cells expressing a MOG-specific
T cell receptor (TCR). Along with myelin peptide, other toll-like receptor agonists
emulsified in IFA. such as peptidoglycan (Vis.ser et al.,2OO5) or CpG
oligonucleotides (Segal et ul.,2OOO), have successfully induced EAE, further
emphasising the necessity of a TLR agonist for disease induction.
To enhance the encephalogenic response, the addition of intraperitoneally injected
pertussis toxin (PTx) is required on the day of immunisation, as well as 2 days post-
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immunisation (Lee and Olitsky, 1955). It has been suggested that pTx facilitates
permeability of the blood-brain barrier (BBB), thereby allowing access of
encephalogenic T cells to the brain and spinal cord (Kerfo ot et al.,2oM; yong et al.,
1993). Other research shows that PTx augments the APC response in lymphoid tissue
and in the CNS' enhancing T cell activation and clonal expansion (Hofstetter er a/.,
2OOZI Regardless of its mechanism of action, PTx clearly augments the disease-
inducing immunisation, resulting in an increased incidence of disease.
The EAE priming process is meant to activate, differentiate, and expand naive T cells
with a TCR-specificity toward MOGrs-ss peptide into encepharogenic Thr cells. The
mechanism behind this specific T cell activation and Thl differentiation lies in the
priming of APCs' such as dendritic cells (DC) and macrophages (MO), wirh bacterial
products within the CFA (as previously mentioned) that stimulate TLRs. At the site
of immunisation, the primary APC responsible for antigen presentation is the DC.
The immunisation ligates specific TLRs on DCs, causing them to mature. Marure
APCs produce large amounts of inflammatory cytokines and mediators including IL-
l,rL-12, and rNF-e. The mature Apcs then migrate to the draining lymph nodes
(DLN) and presenr MoG antigen on MHC II to cD4* T cells (Teugoni et al.. z0ol).
The inflammatory environmenr introduced by the Apcs induces the cD4* MoG-
reactive T cells to respond in a manner considered to be representative of the Ths, or
inflammatory, variety. Once Th1 CD4+ Tcells are activated, they proliferate rapidly
and secrete lymphotoxin, [FN-e, and rNF-e (Juedes et al.,2oo0). These cytokines
further stimulate APCs, causing a positive f'eedback cycle of inflammation. The
activated MoG-reactive T celts circulate throughout the body, constantly scanning
APCs for MoG peptides presenred on MHC II molecules. The numbers of MoG-
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reactive T cells peak in the periphery shortly before the mice display symptoms of
disease (Tugoni et al.,20ol), which occurs approximately 7-10 days after
immunisation in C57BU6 mice.
Because MoG is only found in the CNS, an immunoprivileged site, the MoG-
reactive T cells must cross the BBB to gain access to the antigen-containing tissue.
As mentioned earlier, PTx may aid in facilitating the movement of these cells across
the BBB; however, aT cell can enter the CNS without PTx, but only when activated,
and entry is independent of its TCR specificity (Hickey,lggg). These activated
MoG-reactive T cells migrate into the cNS between day 7 post-immunisation
(Juedes et a1.,2000) and the day prior ro disease onset (Targoni et a|.,2001). once
across the BBB, the T cells recognise MoG presented by various Apcs, both
exogenous (Mo) and endogenous (microglia tMGl). Interestingly, these cNS-
infiltrating T cells show very littre proliferation, if any, in response to myelin
presented on APC's within the cNS (ohmori et al., 1992). Upon TCR stimulation
within the BBB, the activated MoG-reactive T cells respond by secreting
inflammatory cytokines (as mentioned above) and chemokines such as CCL3 and
ccL4 (chavarria and Alcocer-varela, 2004; Karpus and Ransohofl l99g). In
addition, resident APCs secrete other chemokines, such as ccl-2 and ccl-5, that
serve to further enhance T cell activities (Chavarria and Alcocer-varela, 2004;
Juedes et a1.,2000). The chemotaxic cytokine trails draw M@, mast cells, B cells,
and DCs into the CNS. The constant suppty of inflammatory cytokines delivered
back and forth between T cells and APCs leads to repetitive stimulation and massive
destruction of the myelin and myelin-producing oligodendrocytes (ubog u et al.,
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2005), ultimately causing lesions in the perivascular regions of the brain and spinal
cord (Fig. 1.2).
The inflammation cycle does not proceed unchecked, since C57BU6 mice with EAE
do, in fact, recover from disease, albeit only partially. The cause of recovery is
primnrily associated with CD4* CD25* FoxP3* T,"* cells. When T,"* cells are
depleted from mice during EAE, natural recovery is inhibited (McGeachy et a/.,
2005). Moreover. low numbers of CD4+ CD25* cells isolated from the CNS of
recovering mice confers protection from EAE development when these cells are
passively transferred to immunised mice (McGeachy et al.,2AJ5). On activation,
these cells produce potent anti-inflammatory cytokines, including TGF-e and IL-10,
which are believed to be responsible for downregulating inflammatory interactions
between APCs and autoreactive T cells in the CNS (Mekala et al.,200.5:'Zhang et al.,
2004). T,"* cells are currently a topic of intensive investigation, both in EAE and MS,
and multiple subsets of T,"* cells have been identified with varying roles in different
diseases.
From immunisation of autoantigens to recovery from disease, EAE exhibits a
complex pattern of CNS dernyelination comparable to human MS. Sospedra and
Martin (2005) have recently reviewed the factors involved in demyelination during
MS development, and a summary diagram from their paper is reproduced in Fig. 1.3.
The C57BL/6 EAE model provides a consistent disease phenotype by which many
studies have attempted to tease out the complexities of autoimmune interactions.
Current cellular/pathophysiological theories have been described above, but they are
constantly changing or being improved upon as new studies continue to delineate and
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analy$e additional aqpects of ttre disease. F.ot fursier infurmation aoo-ut the cellular
patho'logies of MS and EIAE'pbase refer to the cornprehensive review a;rticle by EI
Be.hi etal-, 2005, whieh datails the activities of the major imrnune cells in both EAE
andMS. U1-timatoly;, the CD4+ Teell rsspgnse tllatis ftrndarnental in the early stages
oJ EAE andrMS has been described rnany ti,mes bef.ore. It is this fundanrental
charaateristic tllat provides a dbfined hrget for novel treatimcnts that n ay directly
translate into a clinical ttrerapy for MS.
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Flgu,re 1.2 Hematoxylin and,eosin (H&E) stained longitudinal smtlons
of spinal'cords. Above are pictures ol a no:r:mal spinal cord (a) and a spinal
eord ftom a rnouse with EAE (b). The white rnattern which contains the
myelinated nerve fibers, is discernible by the long neuronaltracts. Also
labeled is the grey rnatter, and a doJted line is drawn between them for ease
of identification. A typical lesion is circled in Panel b, and is:characterised by
the accurnulation ol nuclea'ted cellular infiltrates. The arrows point to three
small sectjons of red blbod cells in the vasculature (darker pink appearance)-
Autoimmune cell infiltration across the BBB initiates from within the brain
vasculature. These pictures were tdken with a 100x rnagnification.
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Figure 1.3 A schematic interpretation of the molecular and pathological
events that lead to myelin destruction in MS.
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current MS Treatments and Investigational rherapies
The current knowledge of MS is limited by the ability of researchers to perform in-
depth cellul:lr and physiological analyses in patients suffering from the disease.
Although clinical studies on MS have been carried out, many experiments would be
too invasive and unethical to perform in humans. which is why the EAE animal
model is so useful. The EAE animal model has been crucial for the development of
current drugs and for evaluating potential therapies to trear MS (Steinmnn, 1999:
Steinman and Zamvil. 2005). The downside. however, is that not all drugs that are
effective in EAE will have therapeutic effects in MS (Steinman, t999; Steinman and
Zamvil,2005). It is suggested that the rationale behind designing therapies for MS in
the EAE model can be tricky due to the relatively short treatment durations in EAE
and lack of multi-point screening of side-effects in animals (Steinman and Zamvil,
2005). For this reason. drug therapies should target an activity that is presenr in both
MS and EAE.
Glatiramer acetate
All of the current MS treatments have successfully ameliorated EAE by preventing
or blocking a common mechanism found in both diseases. one of the more
successful FDA-approved MS therapies to date is glatiramer acetate which shows a
relapse reduction rate of 307o (Johns on et ol., 1995). Glatiramer acetate consists of
random-length synthetic polypeptides containing fixed molar ratios of four amino
acids found in myelin: tyrosine, grutamate. alanine, and lysine. originally used in an
attempt to initiate EAE, it was found to have the opposite effect. Its mechanism of
action is still unclear, but current studies indicate that glatirarner acetate binds tightly
to MHC II on APCs (Yong, 2(n2).Instead of inducing the typical rh; response
1.5
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found in MS/EAE, the resulting T helper cells take on a Th2 phenotype and secrete
anti-inflammatory cytokines such as IL-4, IL-5. and tL-10. Further evidence suggests
that this tight binding to MCH II by glatiramer acetate causes T cell anergy (Schmied
et ctl..2OO3), probably due to the prevention of antigen presentation to effector T
cells. There are few side-effects associated with glatiramer acetate, and the safety
profile is very clean; however, only 3oo/a of MS patients show any benefit from this
treatment.
Interferon-e
Another FDA-approved treatment that has been used with success rates similar to
those of glatiramer acetate is the cytokine, interferon-e . with only a 30zo relapse
reduction rate, however, it. like glatiramer acetate, is falling well short of an ideal
treatment (Feldmann and Steinman, 2005). Interferon-e works through an entirely
different mechanism compared to glatiramer acetate. The therapeutic action exerted
by interferon-€ prevents upregulation of MHC II on APCs, while downregulating co-
sti m ulatory m olec u les (Yong, 20A4. In additi on, interferon-e has anti-prol iferati ve
effects on T cell clones (yong, 2002).
Natalizumab
One of the strategies employed to treat MS is to target the adhesion molecule e.r-
integrin with monoclonal antibodies. The treatment, called natalizumab, prevents
vLA-4 on autoreactive T cells fiom binding to e4-integrin, ultimately preventing T
cell adhesion and migration across the BBB (von Andrian and Engelhardt, 2003).
Although natalizumab is more successful than the other drugs detailed above, with a
66Vo reduction in annual MS relapse rates, it is closely associated with a rare, but
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potentially fatal disease known as progressive multifocal leukoencephalopathy (pML)
(Bennett, 2006). The saf'ety profile of natatizumab is currently being reviewed by the
FDA in the United States of America. If this drug is approved for all MS patients, it
would have the highest relapse-reduction rate of all clinically available treatments.
one of its disadvantages. however, isi that it must be administered regularly to
maintain a therapeutic effect.
Mitoxantrone and Pixantrone
Another clinically approved treatment for MS is the anti-proliferative compound,
mitoxantrone. Mitoxantrone is a topoisomerase [I inhibitor that decreases overall
numbers of B cells and T cells, as well a.s maintains T cell suppression (Fidle r et al.,
1986; Gbadamosi et a|.,2O03). Mitoxantrone successfully ameliorates EAE and has
had success in MS (Gonsette, 1996; Ridge et at.,l9g5). However, there is an
increasing concem that long-terrn use of mitoxantrone can cause cardiotoxicity
(Avasarala et ul-,2O03). A related altemative drug with no known cardiotoxicity
problems, pixantrone, is proving to be a possible successor to mitoxantrone due to its
greater anti-proliferative effect.s (Cavaletti et al.,2OA4). Until pixantrone is approved
by the FDA, mitoxantrone is the only anti-proliferative drug on the market for
treatment of MS. All of the currently approved treatments fbr MS are summarised in
Table l. l.
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Trade name Generic name Type of drug Mechanism Approx. o/o
ol relapse
reduction
Year of
inroduction
to the market
Copaxone@
Avonex@
Rebi@
Betaseron@
Tysabri@
Novantrone@
glatiramer
acetate
interferon-B 1-a
interferon-B 1-a
interferon-B 1-b
natalizumab
mitoxantrone
Random chain
polymer of
amino acids
Cytokine
Cytokine
Cytokine
Mouse
antibody
Topoisomerase
ll inhibitor
Unknown
Unknown
Unknown
Unknown
Prevents VLA-4
from binding a4-
integrin
Reduces overall
T and B cell
numbers
30-35"/o
30-35"/o
30-35%
30-35%
60-70"/"
30-35%
1996
1 996
2002
1 993
2004
2000
Table 1.1 Current MS therapies.
The reseerch into MS treatments cover various aspects of disease, including simple
remedies such as dietary changes to include more vitamin D or oral tolerance of
myelin antigens, but the treatments extend beyond this to involve the manipulation of
the immune response in general. Other possible therapies might even come from
parasites and associated antigens. Evidence suggests that Scfiistasnmu mansoni
antigens ameliorate EAE through a strong Th2-inducing mechanism via the STAT6
pathway (La Flanrme et al.,2OO3; Sewell et a\.,2O03). There are dozens, if not
hundreds, of treatments that have proven to have some ameliorative effect in EAE
and are currently involved in clinical trials or awaiting approval for clinical trials.
Ideally, the most successful drug will remove autoreactive immune cells and restore
3t
normal immune system activity. This has never been achievecl, leaving anrple room
tbr further rcsearch into a cure fbr MS.
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1.6 Anti-proliferative Agents and the Treatment of Hyper-
proliferative Diseases
As previously mentioned, mitoxantrone is an anti-proliferative agent that has been
approved by the FDA to treat MS. It works by inhibiting the topoisomerase II
enzyme, eff'ectively preventing cell division in interphase by slowing cells in S phase
of the cell cycle and halting cells in G2 phase (Feofanov et al,, 1999). TopoisomerAse
II is one of many possible targets that are involved in cell-cycle control.
One panticular group of anti-proliferative agents that bind microtubules or soluble
tubulin prevents proliferation during mitosis, or M phase of the cell cycle, generally
by disrupting microtubular action. The primary function of microtubules during
anaphase of mitosis is to segregate duplicated chromosomes (pellman. 2001).
Because of this, microtubute disnrption is a popular method to trear cancer.
Chromosomal segregation, however. is not the only role of microtubules. During
normal cell function, microtubules play a major part in scaffolding, migration, and
intracellulau rransporr (.Schitf and Horwitz, l9g0). Although there is a variety of
known microtubule disrupting agents (Attard et a1.,2006). mosr of these compounds
are difficult to obtain or are very costlv.
Paclitaxel
Paclitaxel is a naturally occurring compound isolated from the pacific yew tree
(Wani et al" l97l). It is widely used in the clinical setting as a chemotherapeutic
drug (Bhalla. 2003), and its relative abundance makes it inexpensive and accessible.
The potent anti-tumor activity exhibited by paclitaxel is primarily due to its ability to
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arrest dividing cells in G2l1M phase by preventing microtubule depolymerisation,
ultimately causing arrested cells to apoptose (Bhalla, 2003; Donaldson er eil., 1994:
Fuchs and Johnson, l978; Manfredi et al., 1982; Rowinsky et aI., lggg). While the
focus ofpaclitaxel research has been to targetcancer, cancercells are not the only
types of cells affected by paclitaxel. For example, the proliferation of stimulated
lymphocytes is inhibited after exposure to paclitaxel in cultures (Brown er al., 1985:
Chuang et ul..1994). Patients treated with paclitaxel experience many side-eff'ects,
including a decrease in the number of lymphocytes, likely due to the anti-mitotic
nature of the drug (Kotsakis et a1.,2000; sako et at.,2}}4:Tsavaris et aI.,20oz).
Given these inhibitory effects on immune cell proliferation, paclitaxel may have the
desired immunontodifying activities needed for treatment of EAE or MS. since CD4+
T lymphocytes must undergo mitosis to clonally expand.
Paclitaxel has previously been used as an immunomodifier in autoimmunity. A
micellar formulation of paclitaxel successfully delayed or prevented the onset of
EAE in Lewis rats (cao et al.,2M0). It was theorised that the impact on EAE was
directly related to the anti-mitotic nature of paclitaxel. The authors, however, did not
investigate the mechanisms behind this delay of onset. Other studies found that
paclitaxel could impact collagen-induced arthritis and prevent the onset of disease
altogether (Brahn et ul., 1994; oriver et al., 1994). yet again, the mechanisms of
prevention were not investigated. Although collagen-induced arthritis is an entirely
different disease from EAE, both diseases are believed to be primarily mediated by
cD4n T cells and can be induced by immunisation with a self antigen in cFA
(Ercolini and Miller, 2006; Sakaguchi and Sakaguchi, 2005).
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Pelorusidc A
The novclcompound, peloruside A (peloruside), was discovered in extrriets of
Mycale kentsheli,4 marine sponge that lives in the coastal regiorrs of New Zealand
(west et al.,Zw). Like paelitaxel, peloruside stabilises rnjcrortubules;and has potent
anti-mitotig activity in cancer eell,lines, causing proliferating cells to apoptose in the
Gifvl phase of thecell cycle (Hosd et ar,.,zffil;Hood er al.,z}}z],Although the
suBply, is limited, peloruside is exclusively available for use in selected projects at
Victoria University of Welliuglon. Ttre paclitaxel-like properties of peloruside make
it an in'teres ing r'rlolecule to 6tud-y tor its therap,eutic potential in cancer and other
hy,perprol iferativc disorders, including autoirnmunity.
peloruside A
Figure l,tl structures, ol the anti-mltotic, microtubute-stabitisi ng
e€mpounds, paolitficl and peloruBide A.
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L.7 Aims
Many studies over the years have attempted to dissect every aspect of MS. Due to
limitations in the models used, many assumptions have been made in regard to the
etiology of MS by reference to findings in the EAE animal model of MS. If one
delves into the mechanisms of the two distinct, but similar, diseases. then differences
will undoubtedly be found in their respective pathophysiologies. This is why many
successful treatmenrs of EAE do not directly translate into MS therapies. The
variations in the cellular immunology of MS can vary between patients, similarly to
the variations of different EAE animal models. There are, however, commonalities
that are often overlooked when searching for the next treatment. It is the fundamental
similarities of the two diseases that should be targeted in order to increase the
likelihood of crossover therapeutic success.
The hallmzrrk of any immune response is the rapid proliferation of cells responding to
a foreign antigen. What separates inflammatory autoimmune responses from other
immune events is the fact that they involve lymphocytes that target "self'antigens.
During the initial phases of both EAE and MS, a large number of proliferating
autoreactive cD4'Thrcells are present. In theory, very few immune cells are
normally prolit'erating at any given time in healthy animals. When disease is initiated
in EAE mice. the vast majority of proliferating immune cells should be responding to
self-peptide or adjuvant; thus, targeting cell division in general may have a weighted
effect on this cell population and open doors to therapeutic intervention in EAE and
MS.
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trt is the'in'tontion of this prOject to targer the proliferating cell p,opulations
responeib.le for EAE 
- 
especially cD4" T celis 
- 
with anti-mirotic cornpounds,
specificall.y pdclitaxel and peloruside. If succes$fuI, it is expected that these anti-
mitotic cornpourlds will halt proliferation of autoreactive T cells, either Ferfianently
or tremsiently, rclulting in the full preverrtion or a delayed qnset of EAE.
Additisnally, itis theorised that rnost of the celils of the irnnrUne system will rernain
intact thus the drugs w,ill have a minimal ovefall impact on imrnune syst.em fungtion.
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Chapter 2: General Methods
2.1 Animals, Maintenance, and Ethical Guidelines
All animals were housed and maintained in the animal facilities at Victoria
University of Wellington, New Zea\and, under the guidelines specitied by the
Ministry of Agriculture and Forestry (MAF). Mice were raised in filter-top cages in
temperature-regulated facilities, with maintenance and litter changes performed at
regular intervals. Experimental protocols were approved by the Victoria University
of Wellington Animal Ethics Committee (AEC) under the licenses 2002R6 and
2004R I 7.
Originally purchased from the Jackson Laboratory (Bar Harbor, ME, USA),
C57BL/6 mice were bred at Wellington Schoolof Medicine, Wellington, New
Zealand. Transgenic mice, including toll-like receptor-4 knockout (TLR4 -/-), TLR2
-/-, and zDZ (H-2\ TCR mice, were generously donated by Thomas Biickstriim of
the Malaghan Institute of Medical Research, Wellington, New Zealand. TLR4 -/-
mice are deficient in the major LPS receptor, TLR4; TLR2 -/- mice lack TLR2; and
2D2 transgenic mice have a majority proportion of their CD4* T cells with a TCR
specificity for MOG3s-ss (Bettelli et u\..2003). All mice were bred on a C57BU6
background.
2.2 Reagents
Paclitaxel (purified from laxrrs yanruurcnsi.r), cyclosporin A, and LPS (from E. coli)
were purchased from Sigma Chemical Co. (St. Louis, MO). Taxol@ (Taxol; Bristol-
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Myers squibb, New York city, Ny) was purchased from Capital coast chemists
(wellington, New Zealand). Peloruside, mycalamide, and pareamine were
generously provided by Dr. Peter Northcote (Victoria University of Wellington,
school of chemical and Physical sciences). paclitaxel, peloruside, mycalamide,
pateamine, and cyclosporin A were dissolved in ethanol and stored as t mM stocks
( l0 mM stock for paclitaxel) ar -80'C.
2.3 Primary Cell Preparation and Culture
Dissections/Orean Removal
Animals used for cell preparation were euthanised in a CO: chamber and, after death
was confirmed. immediately transferred to a dissecting table. Animals were wa^shed
with l00o/c ethanol before surgery. Sterility of surgical tools was maintained by
storage in lOovo ethanol during organ removal. The thorax was opened for the
removal of the draining lymph nodes (DLN) and bones. The peritoneal cavity was
opened for the removal of internal organs and tissues such as the spleen (SpL), liver.
kidneys, intestine (INT), mesenteric lymph nodes (mLN), and blood (by cardiac
puncture). Bones, organs, and other tissues were removed by blunt dissociation of
connective tissue' Blood was obtained by cardiac ventricular puncture and extraction
with a 27.5-ga needle and syringe.
The brain and spinal cord were removed following decapitation. The brain was
carefully dissected out of the skull. The spinal cord was removed by pressurised
extraction. Briefly. a pre-filled syringe containing PBS with an attached l9 g needle
was inserted into the lumbar region of the vertebral column. After removal of the
head in the cervical region, positive pressure was exerted on the syringe, forcing the
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spinal cord out of the vertebral column via the cervical opening. The brain, as well as
all other organs except for blood. were transferred to tubes containing either zinc
fixative (see Appendix A) or ice-cold wash media (see Appendix A) for cell
preparation and culture.
Macrophages
Bone marrow-derived macrophages (BMMO) were cultured from C57BL16 mice as
previously described (Celada et a\.,1984). Briefly, long bones were t'lushed with
sterile divalent cation-free Dulbecco's pBS (dpBS) (Invitrogen, Auckland, New
Zealand) with a 23-ga needle. Cells were cultured in complete medium (CTCM; see
Appendix A) in the presence of GM-csF and IL-3 (tiom the supernatanrs of GM-
KLON and WEHI-3 cell lines, respectively). The cells were cultured for 24 hr at
37'C in air with 5Va COz. Non-adherant cells were removed and further cultured for
7-10 days at 37'c in air with 5o/o cot to ailow cells to diff'erentiate into
macrophages. Once a monolayer of cells was established, BMMO were removed by
vigorous pipetting, and 105 cells/ml were resuspended in crCM. cells were then
i,rctivated overnight with 40 U/ml IFN-c in flat-bottom 96-well plates (Falcon,
Franklin Lakes, NJ) ar 37'C in air with SVo CO,.
Solenocvtes and Lymnh Nodes
single cell suspensions of splenocytes and lymph node (LN) cells were enriched by
dissociation of the SPL or LNs through sterile 70-pm cell strainers (Falcon) into 50
ml polypropylene centrifuge tubes (Brunet et al.,1997). For splenocytes, red blood
cells were lysed with red blood cell lysis buffer (Sigma). Cells were resuspended in
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crcM and cul,tured at37',c in airwith svo cotin flat-bottom 96-well plateg
(Falcon) ( lr0F cells/well).
2.4 EAE trmmunisations
To induce EAE, g_12 week old c57BL/6 mioe were ibrmunised with an emulsion of
arntigen in cF'A consisring of 50, eg MoG35-55 peptide (Mimotopes; clayton,. Vic,
Australia), 500 eg heat-inaetivated ttttycobacterium tuberculasis (Difeo Laboratories;
Detroit, MI), 100 el dpBS; and 100 el IFA (Sigma). A ntal of 200 el was injecred
s.c. in ttao hind flanks of each mous€. Ln addition, each mouse was injected i.p. with
200 ag penussis toxin (PTx) (sapphire Bioscience; Redfern, Nsw; Australia) in
specialised PTx buffer (see Apper, dix A) at the time of initial immunisation and
agai'n 48 hr later. The weight of eiuh mouse was recorded daily, as well as
observations made for any signs of clinical disease, from the day of immunisation
u'ntil the day they wene euthanised. The snset of EAE fsllowed a typical pattern in
w,hieh paralysis begau from the tail and graduall;r worked itsiway up theeaudal.
rostral axis. To quantify the level of disease, severity was measured by a typical field
scoring system:
I = Half tail paralysis; loss of rail ronicity
2 = Full tail paralysis
3 
= 
one hind limb paralysis, otr severe weakness in both hind tirnbe
4 = Full hind lirnb paralysis
5 
= Hind limb and front limb paralysis,; moribund
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S:eores wE-r@ recorded daily by ther$ame individual in ordel to reduee nu.bjective
variation. For ethiaalreasons, animals were euthanised if found tobe in a,moribund
state.
2.5 trVleasuring Body Temperature, Weight, ruid Appeararrce of
Xlvilic:e.
Body terqperatures, 
'when require4 were obtained by genthy ineening a lubric,ated
RET{3 recml probe (ADlnstruments) in-ro the anuse.s of rcsbained rnice.
Ternperntures werg rocorded as t. wcights of tlle mice were rneasuredon aMettler
PB 6000 balance (Mettler Tolodo; eolurnbus, OH). The,activity and appearanec of
the rniee were gauged on a pre-detormined scale to uphold Ethical standards
throughOut ex,perirner,rtation. Mou.s€ activitlr was scored as follows:
0r = normal
I = lsw activ,itylslightly weak
2 
= 
limle movemesfllimp to h4lrdle
3 
= 
moribund
Mqrse appeaffice was scored as follows:
0.= normalr
I = lackof groorning (sltghtly greasy coat)
2 
= 
to,tal track of hygiene (very greasy coat, rougfud up rrce)
iWicewe.reeuttlanisedif they had,al}Voweightloss,andacombinedscsreof e 3for
activnty,irnd appearanca
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2.6 Enzyme-Linked Immunosorbant Assays for Cytokine Analysis
A Pharmingen sandwich ELISA was used to measure cytokines produced by cells in
culture fbllowing the manufacturer's recommendations (BD Pharmingen; Franklin
Lakes, NJ). Briefly, supernatants from cell cultures were removed and stored at -
20'C. Samples were stored at 4'C if they were to be used on the day of the ELISA
measurement. To prepare the ELISA plate (Greiner; Monroe, NC), a cytokine-
specific capture antibody was diluted in capture buffer (see Appendix A) and
transf'erred to 96-well plates. The plates were then incubated at 4'C overnight. Wells
were rinsed with Tween-PBS (TPBS). In order to block non-specific binding, wells
were incubated for 2 hr with PBS containing 5a/o FCS. Afier a TPBS rinse, samples
were added directly to the wells, or diluted with 57o FCS in PBS solution. then added
to the wells. Afier 2 hr, plates were washed in TPBS. Diluted biotinylated detection
antibody was added immediately after the last wash. followed by a I -hr incubation.
Plates were re-washed in TPBS, followed by a 30-min incubation with the
recommended dilution of streptavidin-HRP (SA-HRP). A final wash in TPBS was
performed. Lastly, substrate reagents "A" and 'oB" were added to induce a color
change that directly correlated to cytokine concentration, followed by the addition of
0.18 M sulfuric acid to stop the reaction. Well absorbances were read on a VersaMax
plate reader (Molecular Devices; Sunnyvale, CA, USA) at a wavelength of 450 nm.
2.7 Metabolism and Proliferation Assavs
MTT colorimetric assav
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MTT (3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyrtetrazolium bromide) is n
tetrazolium salt that reduces to purple formazan in the presence of reducing
compounds, such as NADH and NADpH (Berridge et al.,2oa5; Hansen et al., l9g9:
Mosmann, 1983). Dose-response curves were obtained by comparing drug-treated
cells to untreated controls following the addition of MTT to cultures. Sirnilarly,
metabolic activity of non-proliferating cells, based on the relative presence of
reducing compounds, was assayed with MTT in BMMO cultures.
A GyQUANT kit (lnvitrogen; Auckrand, NZ) was used as an alternative assay to
detect cell proliferation when total ceil numbers were limited. This assay was
performed following the manufacturer's recommendations. CyQUANT measures the
total DNA content of a culture. which detects proliferation in cultures with low cells
numbers (<5 X l0s total cells). Briefly, 2 X 105 cells were cultured in a 96-well plate
with CTCM (37'C in air with 5To CO). After 72 hr, the supematants were removed
and the plates containing the cells were stored at -20'C. To perform the assay, the 96-
wellplates were removed from the -20"C freezer, followed by incubation with the
CyQUANT lysis buffer. The detection reagent, a green-fluorescing dye that binds to
cellular DNA. was then added ro each well. The light absorbance of the 96-well
plates were detennined on a spectraMax Gemini fluorescence plate reader
(Molecular Devices; Sunnyvale, CA, USA) with excitation/emission wavelengths of
48Ol 520 nm, respecti vely.
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2.8 General FACS Analysis
Stained cells were examined in a FACScan f'low cytometer (Becton Dickinson,
Franklin Lakes, NJ). In brief, 10,000 cell events were collected for each assay, and
the data were analysed by CellQuest Pro software (Becton Dickinson).
Fluorescently labeled antibodies (BD Pharmingen) were incubated with cells
according to the manufacturer's recommendations. Each sample was stained with
either a fluorcscently labeled antibody or an isotype control to correct for
autofl uorescence and background staining.
2.9 Histology
The tissuesiorgans used for histology were removed from mice and were preserved
in zinc fixative (Appendix A). Paraffin embedding, slide preparation, and
hematoxylin and eosin (H&E) staining were performed by the Pathology Department
at the Wellington School of Medicine and Health Sciences, Wellington, New
Zealand. Lesions in spinal cord tissue from mice were identified, measured, and
counted. [n addition, an zrverage severity score was assigned for each lesion present
in an affected spinal cord (Fig. 2. I ):
Q = normal; no cellular infiltrates
t = mild; < 50 em diameter foci of infiltrating cells in the perivascular region.
2 - moderate; 50 em 
- 
100 em diameter foci in the perivascular region.
J = severe; large foci (> 100 em) in the CNS parenchyma
It was expected that this method of determining the severity of spinal cord
inflammatorv cell infiltration would be subiective. and therefore the individual
5r
mouse disease score-s were not compared until lesion scoring, was comple.ted for all
samples. It was also recognised that spinal cord lesions were 3-dimensional, thus
rneasu.ring the size o.f the lesion foei in the particular dimension on the slide would
not necessarily represent tt e actual size of the entire lesioq however, using this
metho4 the relative sizes and abundance of lesions can be grrantified and compared
acro$s all sample groups,
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Flglre 2,I Examp.ls of tt g
thonm abote are a norm,al;spinatoord,
,lesion (e), and a sevgreleclon (d). The,
& b)'or il00 <m (GS d},
@lf fppi,
(al, a nnrtd leEion (b)i:dynoderirre
lrellowsoa.le bare represent SOrg.r,n (ia
For hu,utunohistochonristry; (.trIq[ panaffim,ernbedded fi ssucs nrcre depareffi,nilssd
utd rcftydrated. Sli-d_eg comainirry tho tiLssue w,ere then blocked. vs'ifr I % lB$A fu FH$;
ffollblrred by inerrhation wlrh a biotiqy,latd rrntibdg,. ABc mgente (v.ccmrr
nabo-rflnsrics, Brutrlingarne, GA) aud D-A$ $dfuirioa ($,is,g[a) w,ere uaedfoll,owing the
rnarnrfac'Efer$' iecsriimordatijons for qiluib,ody de,wsfitur. D.Aliistaining:appearc
hru o undeir a tright rnicroseope. Dvleitryl gr6s_[r which srains,.els6matitt; qfae u6pd,as
s eouutsffi,flh fo_r,s.&ll-tllllir, nue.leii.,
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2.10 Graphing and S"tatisfical Analy'ses
GraphPad Prism (Version 4.0, Graphpad Software, [nc.; San Diego, CA) w4s used 0o
determine significanee of data. SigmaPlot (SSP'S Scienoe; Chicago, IL) was used for
data manipulations and graphing. All data points are expressed as the mean t
standard error unles-s otherwise noted.
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chapter 3: rmmunomodulatory Effects of the Anti-
Mitotic Compounds, Paclitaxel and peloruside.
3.1 Introduction
Pateamine, mycalamide, and peloruside are cytotoxic compounds isolated from
Mvcale hentsheli (west et u|.,2000). previous studies have suggested that
mycalamide and pateamine exhibit immunosuppressive properties (Galvin et al.,
1993; Romo, 1998; Romo et al.,2Cf'4); however, Hood er at. (2002) showed that
pateamine and mycalamide were not directly immunosuppressive in a mixed
lymphocyte reaction (MLR). while few studies have investigated the
immunomodulatory activities of pelorusicle, Hood et al. (2002) showed that
peloruside non-specifically reduced IL-2 production fiom lymphocytes by inhibiting
proliferation in a MLR. In these studies, there was no mention of the lymphocyte
subsets that were directly affected by peloruside.
Paclitaxel has a long clinical history in the treatment of cancer. paclitaxel is known
to be cytotoxic to proliferating splenocytes and cancer cells at concentrations in the
nM range in vitru (Brown et ut., l9g5: Horwitz et al., 1993). Another property of
paclitaxel is that it mimics bacterial lipopolysaccharide (Lps) in murine
macrophages and DCs by binding to the TLR4 complex (Byrd-Leife r et al., z00l;
Ding er al.,1993:' Joo, 2003). The LpS-mimicry observed with paclitaxel is
detectable in vitro at concentrations above I eM. and suggests that paclitaxel may
play an immunomodulatory role in vivo.
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Aims
Peloruside. as well as the structurally unrelated compounds mycalamide and
pateamine, are cytotoxic agents isolated from a Mycale sp. of marine sponge (West et
al.,Z00,O). Mycalamide and pateamine have been identified as having
immunosuppressant activities (Galvin et at., 1993; Romo, l99g; Romo et u1.,2004).
To confirm whether these 3 compounds exhibit immunosuppressive activities,
peloruside, pateamine, and mycalamide were compared to a known
immunosuppressant. cyclosporine A, to clarify the nature of immunosuppression in
all of these compounds.
Although the mechanism of microtubule-stabilisation has been elucidated for
paclitaxel and peloruside (Bhalla, 2003; Donald.son er at.,1994: Fuchs and Johnson.
1978; Gaitanos et a\.,2004; Gligorov and Lotz,2004; Hood et ttl.,Z}o2;Manfredi er
al., 1982; Rowinsky et ul.. 1988: schiff et al., 1979; schiff and Horwitz, l9g0), there
are very few studies looking at other bioactive roles for peloruside. specifically
whether or not it induces a pro-inflammatory response similar to paclitaxel.
Therefore, in order to understand how petoruside impacts on cells of the immune
system, the following set of experiments was designed to compare the effects of
pacfitaxel to peloruside in murine M@ and splenocytes. This includes identifying
immune cell populations susceptible to the anti-mitotic effects of both compounds, as
well as assaying for immunostimulation.
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3.2 Methods
3.2.1 Anti-CD3 T cell receptor stimulation
Splenocytes from C57BU6 mice were isolated as described in Chapter 2. T cells
were activated by cross-linking of rCRs ro plate-bound anti-cD3e antibody (e-cD3)
(0.5 e g/well) (hamster mAb 145-2Cl I, BD Bioscience, Franklin Lakes, NJ). Cells
were immediately cultured in the presence of peloruside, mycalamide, pateamine, or
cyclosporine A at a range of concentrations for 24hr or 72 hr (in the case of
mycalamide and cyclosporine A). Cultured cells in triplicate wells were pooled for
FACS analvsis.
3.2,2 FACS analysis
FACS analyses were performed as described in chapter 2.g. In brief, CD4+ and
CD8* T cells were identified by fluorescently-labeled anribodies (BD pharmingen).
cells were stained with annexin-v:FITC (Roche; Germany), which binds
phosphatidylserine. and the DNA-binding salt propidium iodide (pl) (sigma) prior ro
FACS analysis. Together, these stains act as apoptotic markers. Cellular debris was
gated out based on a size threshold (see Appendix c). Each test sample was
accompanied by a time-matched control sample (cells not treated with drug).
3.2.3 Stimulation of T cells in splenocyte cultures
Spf enocytes were isolated from the spleens af C57Bl-/6 mice (described in Chapter
2). cells ( l06/well) were culrured in a 96-well plate (Falcon) with 3 eg/ml of the T
cell mitogen, concanavalin A (Con A; sigma), and dilutions of peloruside or
paclitaxel. After a 72-hr incubation period (conditions described in Chapter 2), a
MTT proliferation assay was performed on the cells.
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3.2.4 Assessment of cell viability, metabolism, and proliferation
Viability of e-CD3-stimulated splenocytes was determined by FACS analysis and
expressed as the number of gated annexin-V "'s CD4*/CD8* cells divided by the total
number of cells compared to an untreated. time-matched control (see Appendix C).
Metabolism and proliferation were determined by the MTT assav (describecl in
Chapter 2).
3.2.5 IFN-u, TNF-c, lL-lZ,IL-lO and NO detection
All ELISAs were pertbrmed following the manufacturer's recommendations (see
chapter 2) (BD Phermingen). Anti-mouse antibodies againsr IFN-g, TNF-c , tL-
12p40, and IL-10 (both capture and detection) were raised in rats, and none show any
known cross reactivity to other cytokines. All ELISAs were performed within the
recommended linear detection Iimits of the respective kits. The accumulation of
Nor-, an indicator of No production in the culture medium, was assayed bv the
Greiss reaction (Creen et al.,lgBZ).
3.3 Results
3.3.1 rhe effect of mycale sponge metabolites on T cell receptor signaling.
Metabolites from Myc:ale hentsheri, including peloruside, mycalamide and
pateamine, werc tested for immunosuppressive activities alongside the known
immunosuppressant, cyclosporin A. Splenocytes were stimulated by plate-bound e-
cD3 antibody, which acts as a cD3 agonist, and bypasses rhe need for MHC plus
specific peptide. The MTT cell proliferation assay was used to assess effects of the
compounds on T cell proliferation, and annexin-V/PI binding was used to determine
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the proportion of viable. non-apoptotic cells. Annexin-V binds to phosphatidylserine,
which is normally on the inner layer of the plasma membrane, but during the early
stages of apoptosis, phosphatidylserine translocates to the extemal membrane of the
cell where it is accessible for binding to annexin-V. The use of pI, which binds to
DNA, difl'erentiates the cells with membrane damage from apoptotic cells since pI
will only stain DNA if there is membrane disruption such as occurs during necrosis,
or if the cell is in late apoptosis. IFN-y production was used as a marker of TCR-
sti mulated cytokine production.
Peloruside and pateamine inhibited e -CD3-stimulated T cell proliferarion and IFN-6
production (Fig. 3.1 a-b). but did so by causing apoptosis. Unfortunately, however,
this particular stock of peloruside was discovered to contain a highly cytotoxic
contaminant (see Appendix B for details); therefore, Fig. 3. I a was erroneous data. In
the case of mycalamide and cyclosporin A, however, [FN-e production was
completely inhibited at the higher concentrations tested, with T cell viability never
faf f ing below 30%t af the untreated controls after a 24-hr treatment (Fig. 3. I c-d).
Mycalamide inhibited cell proliferation to a greater extent than cyclosporin A.
Longer exposures of 72 hr completely inhibited cell proliferation (MTT assay);
however, cell viability remained high (367o for mycalamide at l0 nM and Z8o/o for
cyclosporin A at 1000 nM) (Fig. 3. t e-f). This suggests that mycalamide, like
cyclosporin A, has immunosuppressive propertie$, defined by reduced proliferation
and [FN-e production without causing cell death. Although peloruside results were
negated, the other sponge metabolites and cyclosporin A are valid, and are shown
because they alre metabolites from the same sponge and may have a direct effect on T
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cell activation. All further peloruside experiments w€re perforrnerl with a different"
non.contaminated stock of peloruside.
To identify if there was seleetive inhibition of ly.qlphocytes, software-generated
selectivity gates were placed on CD4* and CD8* T c-ells in FACS analyses (see
Appendix C for gating). The respective viabilities of the two T cell subsets were
similar (data not $hown), and the,cells w€re therefore grouped for analysls pu(po$esi
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Figure 3.1 Anti-CD3-stimulated T cell responses to sponge metabolites and
cyclosporin A. lsolated spleen cells were stimulated to divide by cross-linking to
0.5 pg/ml s-CD3 antibody per well of a 96-well plate, immediately followed by
treatment with cytotoxic drugs. T cell proliferation (open triangles) was measured by
the MTT assay atter 24 or 72hr of culture. T cell viability, assessed as the annexin
V-unstained proportion (open squares), was analysed by flow cytometry. IFN-s
(filled diamonds) was determined by ELISA, and the mean and SEM of 3 separate
experiments performed in triplicate are presented. All results are expressed as the
7" of an untreated control. Peloruside data (a) is erroneous due to contamination.
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Mycalamide (24 hrs)
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3.3.2 Peloruside and paclitaxel are cytotoxic to proliferating splenocytes.
using the MTT cell prolif'eration assay, 72-hr IC50 values of peloruside and
paclitaxel were measured in proliferating splenocytes to determine if these
compounds can inhibit T cell proliferation without being cytotoxic to unstimulated
cells. Paclitaxel and peloruside were cytotoxic to Con A-stinrulated splenocytes with
IC50 values of 30 nM and 83 nM, respecrively (Fig. 3.2 a). The ICso values for con
A-stimulated splenocytes were determined by nonlinear regression. The minimum
absorbance values were as low as 4OVo of the control, but never reached 0Zo. This is
likely due to the nature of con A stimulation. T cells comprise about half of
splenocytes and Con A is a T cell mitogen, which leaves many cells in a splenocyte
population unstimulated, thus not susceptible to the anti-mitotic effects of peloruside
and paclitaxel Little to no cytotoxicity wtrs observed in cultures of unstimulated
splenocytes treated with either drug (Fig. 3.2 b).
3.3.3 Peloruside does not induce the release of pro-inflammatory cytokines by
BMMO.
Because paclitaxel, in addition to its microtubule stabilising effects, can mimic LpS
in thioglycolate-elicited peritoneal murine macrophages and cause the release of pro-
inflammatory cytokines (Byrd-Lrifer et al.2001), BMMO were cultured with
paclitaxel or peloruside at a wide range of concentrations to assess whether
peloruside has similar LPS mimetic properties to paclitaxel. [n agreement wirh the
literature, paclitaxel cau.sed the production of tL- l?p40 and No in lFN-e-activated
BMM@ (Fig. 3.3 a and b). surprisingry, no TNF-e was derectable at g hr in the
supematants of BMMO when cultured with a range of paclitaxel concentrations up to
l0 eM (Fig. 3.3 c): however. TNF-e was detected at 2 hr from cultures containins l0
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e M paclitaxel (Fig. 3.3 d). In BMMO cultured with peloruside. there was no lL-
12p40, NO. or TNF-c detected. Additionally, the anti-inflammatory cytokine IL-10
was not detected in supernatants of either peloruside- or paclitaxel-treated cells (data
not shown).
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Figure 3.2 Determining lcso volues of peloruside and paclitaxel in
splenocytes. Peloruside (filled circles) or paclitaxel (open squares) was
cultured for 72 hr with splenocytes that were stimulated with 3 <g/ml Con-A (a)
or unstimulated (b). Both peloruside and paclitaxel inhibited proliferation of
stimulated splenocytes (a) with little to no cytotoxicity in unstimulated
splenocytes (b). Data points are representative of duplicate or triplicate wells
lrom3-4experiments.
LPS stimulates BMMO primarily through tolllike receptor-4 (TLR4), resulting in
the release of pro-inflammatory cytokines. To confirm that paclitaxel was acting
directly on the TLR4 complex in its LPS mimicry, these experiments were repeated
on BMMO from TLR4 -/- and TLR2 -/- mice (Figs. 3.4 and 3.5). Not surprisingly,
the absence of TLR4 on BMM@ cultured with paclitaxel (Fig. 3.4) completely
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ablated cytokine produetion.'There was no dif.ferernee in ttre production o.f
inflarnuratory rnediators by TLR2 -/- and wild-type BIVIN{@ in response to paclitaxel
(Fig, 3.4), and,again, peloruside had no effeot onIL-l?, NO orTNF-e production by
TLR2 -| or TLR4 + BMM@ (Fig. 3.5). To detErrnr'ine whether the absenee of
cyrtokines in.s.upernatantsof'BMM@ culturcd with peloruside was due to general
cyrotoxicity, the viability of drug-s)(posed BMMQ was assayed by MTT reduction,
After a 72-hr ine,ubationr neither peloruside (Fie. 3.5 d) nor paclitaxel (Fig. 3.ut d)
were oytotoris to BMM@. Interertingl!, corcenE&tisns of pactitaxol in the eM range
produced up to.a Z'fold increase in MTT rcduction in wild-type,and TLR2y'- cells"
indicating a large increase in reducingegmpaunds such as NADH and NADPH
w,ithin these BMM'@, thus suggesting enhanced nrretabolic activity. This enhanced
activity was not seen in splenocytes (Fig. 3.3). These resutrts indicate that Atnougtt
paclitaxel and plonrsideshare a similar anti-mitotic mechanisrn o micrstubule
stabilisatiorL peloruside does not share the LPS mimicry of paclitaxel.
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Figure 3.3 Effect of peloruside and paclitaxel on BMMO. IFN-s
activated BMMO (5 X 104 cells/well) were cultured with either peloruside
(s) or paclitaxel (s) at a range of concentrations. The response to LPS
(20 ng/ml) on its own is presented for comparison. Paclitaxel, but not
peloruside, induced the production of lL-12p40 (a), nitrite (b), and TNF-
s (d) from BMMO. No TNF-< was detected from BMMO after I hr
culture with paclitaxel or peloruside (c); however, TNF-s was present in
paclitaxel-treated cultures at 2 hr (d). NO and cytokine levels were
determined as described in Materials and Methods. Results are
representative of duplicate or triplicate wells from 4 - 8 experiments. ***
P <0.001 compared to no drug, as determined by the Student's t-test
with a sequential Bonferroni correction.
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3,3.4 Both peloruside alnd pactitaxel culhrred wiun- BMM@ decrwe levels of
TNF.o and NO productionin theprsencn of LpS.
To detemine if paelitaxel orpeloruside could alter LP$-induced pro-inflammatory
cytokine produc'tion, both compouuds were adde'd to aultures of LPS-stimulated
BMMO. When cultured with either paclitaxel or peloruside under ttrese conditions,
decreased levels of TNF-e and, to a lesser extent, NO were obsefved eompared bo a
control with LFS alone (Fig. 3"6 a.b), The observed effect sf decreased TNF.g ,and
NO production was only seen at [.PS concentialions less than or equal to 20 ng/ml.
Wllen Bl\dld@ were cultured with LPS concentrationshiglur th,irn 20 ng/ml, the anti-
inflamnaabry effccts of the trno (!rugs were no,longer sbserved (data ilot pne$enrcd).
Interestingly, while peloruside and pactitaxel decreased TNF-g and NO production
ftom LPS-stimulatedBMM0, nsither dnrg had any obvious effect on ll--l2p4o
produedon frsm theee sanre celle (Fig, 3.6 e). Finaily,, similar to prevlous
'experiments (Figs. 3..4 d and 3.5 d), BMN4@ rreared with high ooncenrratio.ns of
paolitaxel ehowed an enhanced rn"etabolic activlty above the levels seen with LpS
alone (Fig. 3,6 d).
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Figure 3.4 Paolltaxel in BMMO.
A range of paclitaxel concentrations were cultured with IFN-g
stimulated BMM@ from wild-type (open circles), TLRZ -/- (ctosed
circles), and rLR4 -/- mice (open triangles). supernatants from these
cultures were removed and concentrations of lL12 after g hr (a), nitrite
after72 hr (b), and rNF-s atter z hr (c) were determined. A MTT assay
after7? hr was perforrned to determine ceil metabolism (d). Results
are representative of triplicate samples from 3 experiments.
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Figure 3.5 Peloruside in BMMO.
similar to Figure 3.4, IFN-+stimulated BMM@ trom wild-type (open
circles), TLR2 -/- (closed eircles), and rLR4 -/- mice (open triangles)
were cultured with a range of peloruside concentrations. super.natants
from these cultures were removed and concentrations of lL-12 after g hr
(a), nitrite after 72 hr (b), and rNF-s after 2 hr (c) were determined. A
MTT assay atler 72 hr was perforned to determine cell metabolism (d).
Results are representalive of triplicate sarnples from 3 experiments.
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Figure 3.6 Effect of peloruside and paclitaxel in Lps-stimutated BMMO.
BMM@ from wild-type mice were curtured with 20 ng/ml Lps and either
peloruside (s) or paclitaxel (<) at a range of concentrations. Both compounds
caused a significant decrease in levels of TNF-S (a) and nitrite (b) at higher
concentrations. lL-12p40 was unaffected by either drug (c). paclitaxel also
enhanced metabolic activity (d). Cytokine levels were determined by ELISA after
8 hr incubation. No (b) was determined by Greiss reaction after 72 hr. The MTT
assay (d) was performed as described in Materials and Methods after ZZ hr. All
vafues are expressed as ao/" of drug-free Lps-stimulated control BMMO.
Results are representative of duplicate or triplicate wells from 3 - S experiments.
* P <0.05, ** P <0.01, *** P <0.001, compared to Lps stimulation on its own, as
determined by the Student's t-test with a sequential Bonferroni correction.
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3.4 Discussion
3.4.f Immunosuppressive properties of sponge metabolites
Peloruside inhibited [FN-e production from e-CD3-stimulated T cells. primarily by
causing apoptosis. Later experiments, however, determined that this peloruside stock
had a potent cytotoxic contaminant (Appendix B), therefore invalidating these results
with peloruside. Interestingly. pateamine was not found to be immunosuppressive as
previously reported (Romo, 1998; Romo et u1.,2004). The relevance of pateamine to
this project is limited, other than its use as a control cytotoxic compound from the
same source as peloruside. Pateamine has been found to be a protein synthesis
inhibitor that blocks the function of the initiation factor, eIF4A (Bordeleau et a/.,
2005). Mycalamide and cyclosporin A, although immunosuppressive in their mode
of action, ue also used a.s controls in the present study, mycalamide as another non-
microtubule stabilizing cytotoxin and cyclosporin A as a true anti-inflammatory
agent. Mycalamide, like pateamine, is a protein synthesis inhibitorbut interacts
directly with the ribosome (Bunes and Clement, 1989).
One previous study looked irt possible immunosuppressive effects of peloruside
using a one-way MLR (Miller et a1.,2004). The MLR is a proliferation assay that
takes advantage of immune responses from allotypic cells. The responding T
lymphocytes will proliferate in response to foreign peptides displayed on the
allotypic MHC molecules located on APCs of the stimulator population. This method
of stimulation is selective, in that the only T lymphocytes that respond are those with
specific TCRs to the foreign peptides or those capable of recognising the allotypic
MHC, a reactive subset that is normally between l-lOVa of the total T cell
population. This experiment provided valuable information on anti-proliferative
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responses of peloruside, but did not identify specific subsets of lymphocytes that
were affected by the compound.
The method employed here used e-CD3 antibody stimulation of splenocytes. This
causes nearly all T cells in the mixed population of splenocytes to proliferate due to
the direct stimulation of the TCR via e -CD3. eliminating the need for APCs and
decreasing the variability often seen in the MLR. [t was hoped that the data generated
from this experiment would determine if there is a specific immunosuppressive eff'ect
in CD4* or CD8n T cells in response to peloruside. Gates for CD4* and CD8'cells
were set and independently observed in the FACS analyses. Because the compounds
used in these experiments were equally cytotoxic to both populations of T cells in a
dose-dependant manner, the populations were combined and treated as a single
population of T cells. No direct immunosuppression was observed from pateamine or
the contaminated peloruside as shown by the concomitant decrease in IFN-e and
viability. Mycalamide, on the other hand, reduced prolit'eration and decreased IFN-e
production without compromi.sing cell viability, similar to the cyclosporin A control,
suggesting that further research into the immunosuppressive activities of mycalamide
are warranted.
3.4.2 Effects of peloruside on Con-A stimulated splenocytes
Since the new stock of peloruside had only been tested for cytotoxicity in a
preliminary experiment (see Appendix B), it was cultured with splenocytes,
alongside paclitaxel, to confirm its cytotoxicity. Peloruside was cytotoxic to
proliferating splenocytes tiom Con-A stimulation with an ICso value of 83 nM.
Paclitaxel was also cytotoxic at an IC56 value of 30 nM. These lCso values are
7l
comparable to what has been previously reported for peloruside (lCso = I nM - 66
nM; Hood, 2002; Gaitanos, 2005) and paclitaxel (ICso 
= 2 nM - 53 nM; Gaitanos.
2005) in cancer cell lines in this laboratory. tt is important to point out thar Con A is
a T cell mitogen, and splenocytes are typically comprised of 30vo T cells. 6oa/o B
cef ls, and the remainin g loo/o are other leukocytes. As expected, complete ablation of
MTT reduction did not occur in Con A-stimulated splenocytes treated with drugs at
the higher concentrations (Figs. 3.2 b). Although, paclitaxel has been shown to be
immunosuppressive on the basis of its cytotoxicity to proliferating B cells (Lee et al.,
2000), there is conflicting evidence as to whether or not it is cytotoxic to
prof iferating T cells. In the studies by Lee et at.(.2ooo), pacliraxel-induced
cytotoxicity was not seen in Con A-stimulated splenocytes, contrary to what had
been described previously (Brown et al.,1985). In the present study, the cytotoxicity
of paclitaxel was confirmed in Con A-stimulated splenocytes with an IC-1 value of
30 nm. This value is in line with what others have seen using paclitaxel in cancer cell
line cultures (Gaitanos, 2005; Gaitanos et u\.,2004; Hood, 2002; Jordan et al., 1993).
These studies and those of this thesis support the idea that anti-proliferative
compounds may be of benefit to inflammatory autoimmune disorders by taygeting
the dividing populations of autoreactive T cells that mediate many of these diseases.
3.4.3 Effects of peloruside in BMMO
Peloruside' in contrast to paclitaxel. does not activate murine BMM@ to release the
pro-inflammatory mediators TNF-c , rL-llp4o and NO. The MTT re<lucrion assay
confirms that neither peloruside nor paclitaxel is cytotoxic to BMM@, and moreover,
paclitaxel causes an increase in reductive metabolism in the I to l0 eM
concentration range, possibly due to the induction of the pro-inflammatory
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machinery. when BMMO were cultured with Lps and either drug at low eM
concentrations, there was a decrease in the production of TNF-g and NO, but not tL-
l2p4o. An interesting observation that followed from these results was that greater
than 20 ng/ml LPS completely overshadowed the TNF-c -reducing effects of
paclitaxel and peloruside (data not shown). Taken together, these results indicate that
unlike paclitaxel, peloruside does not induce the production of pro-inflammatory
mediators and like paclitaxel, specifically reduces TNF-g and No production by
BMMO at lower concentrations of the drug.
Both paclitaxel and peloruside are known to be cytotoxic to proliferating cells by
binding to a site on microtubules and preventing tubulin depolymerisation.
Peloruside binds ro a site on tubulin distinct from paclitaxel, although the
microtubule stabilizing effect is similar (Gaitanos et al., 2004; Hood er al.,2oaz:
Jimenez-Barbero et a1.,2006:' Pineda et al.,zoo4). until now, however, there have
been no investigations into the effects of peloruside on non-proliferating cells such as
macrophages. The immunomodulatory effects and cytotoxic nature of paclitaxel. on
the other hand, are well characterised. lts ability to cause apoptosis in dividing cells
by binding to microtubules and preventing depolymerisation has made paclitaxel one
of the most successful treatments for cancer to date (Gligorov and Lotz, zC/|,4).
In addition to its tubulin-binding properties, paclitaxel also stimulates the murine
TLR4 complex in a manner nearly indistinguishabte from LPS (Byrd-Leifer et al.,
2001). This stimulation occurs with concentrations of paclitaxel in the low e M range,
causing murine BMM@ to release inflammatory cytokines and NO. In these
experiments we found TNF-c in BMM@ supematants after 2 hr but not 8 hr exposure
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to paclitaxel. Other studies have reported higher levels of paclitaxel-induced TNF-g
production for more prolonged periods (Bogdan and Ding, 1992;Byrd-Leifer et al.,
2001). These discrepancies may be due to the use of thioglycolate to elicit peritoneal
macrophages in the aforementioned studies (Bogdan and Ding, 1992; Byrd-Leifer er
ul.,2o0l), as thioglycolate is known to induce an inflammatory phenotype (Loke and
Allison, 2003). The enhanced metabolic activity of BMM@ in response to paclitaxel
has never been shown before, although it is not surprising that the energy
requirements of an inflammatory response would increase the production of NADH
and NADPH, thus enhancing MTT dye reduction (Berridge et a1.,2005).
since paclitaxel by itself induces an inflammatory response in BMMO, it was
important to determine if it synergises with LpS to enhance inflammation.
Surprisingly, both paclitaxel and peloruside had no effect on the release of IL- lhp40
from BMMO cultured with LPS, but both drugs reduced the tevels of TNF-e and NO
in these LPS-stimulated BMMO without being cytotoxic. The reduction of No was
significant. but not nearly as marked as the reduction of rNF-e. The mechanism
behind NO reduction may have to do with the reduction of TNF-e, as the production
of inducible nitric-oxide synthase (iNOS) 
- 
the enzyme primarily responsible for NO
synthesis in MO 
- 
is a downstream effect of rNF-e (vila-Del sot er al., 20o6\.
Although it is difficulr to speculate at this time, one mechanism by which these
compounds may specifically affect TNF-g production is through microtubule-
mediated secretion of TNF-c by BMM@ when stimulated by LPS. previous studies
have shown that the microtubule depolymerising compound, colchicine, inhibits
macrophage production of rNF-e, GM-csF, and IL-6 in response to Lps (Rao et al.,
1997).ln contrast to the results presented here, no change was found in NO levels in
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the study by Roa et al.his likely that the I.PS response has a mierotubule dependent
and independent set of pathvays. Similarly, microtnbule stabilisati,on may be
responsible for the decrease in LPS-induced production of TNF-c in response to
peloruside or paclitaxel. Frevious studies have estabtished that TJ-.{F-e is a rate-
li niting step in the pro-inflammatory process, and neutralisatisn of TNF*e by
monocjonal antibodies cauges a narked nmelioration in several autsimrnurp diseases
(Feldmann, zm3-), as well as decreases paclitaxel-mediated NO p'roduction by
perttoneal macrophages (Mullins et aI.,1991). In addition, neuffiisation of TNF-e
also cau$os a reduction of GM-CSF and IL-6 (Feldmann et ail.,I996) in a similar
manner to what has been observed with microtubule-depolymerising aompounds.
The findings presented herein raise the possibility that selective microtubule-
stabilising cornp-ounds, such as peloruside, but nst paclitaxel, may, in addjtion m
having aati-mitotic effeets on T cell population, 
-be able to itnpact sn infl'ainmation as
well by preiventing secretion of TIrlF.-e and the cascade of inflammatory mediatom
,that follow.
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Chapter 4: In Vivo Immunomodulatory Effects of
Paclitaxel
4.1 Introduction
Paclitaxel is an extremely hydrophobic molecule. Because of this, it must be
dissolved in solvents such as ethanol or DMSO. The clinically-used formulation of
paclitaxel (Taxol@) is designed to overcome the challenges presented by the
hydrophobicity of the compound. Taxol is comprised of paclitaxel dissolved in
ethanol and Cremophor EL ( l : t ), diluted 5- to 20-fold in saline. Cremophor EL itself
is not without effects. as it is known to cau.se hypersensitivity reactions (price and
Castells, 2002).
The LPS-mimicking inflammatory effects of paclitaxel, as shown in Chapter 3. are
clearly demonstrated in vitro by others (Byrd-Leifer et a\.,2001; Manthey et al.,
1994; Perera et ctl.,l996). Surprisingly, however, there are few studies investigating
paclitaxel-induced LPS-Iike roxicity in vit,o. Mullins et al. (l99gb) found thar
splenocytes fiom Taxol-injected mice showed a decreased proliferative response
when isolated 24 hr after injection. In addition, splenic macrophages isolated from
these same mice showed enhanced NO production compared to untreated animals
(Mulfins et al., 1998a). There was no effect seen in control animals receiving
Cremophor EL or saline. Taken together, these results suggest that Taxol exerts both
anti-proliferative and inflammatory response s in vivo.
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As mentioned previously, one study looked at the use of a cremophor El-free
micellar formulation of paclitaxel to treat Lewis rats immunised to develop EAE
(Cao et a/., 2000). This study fbund that paclitaxel was capable of decreasing the
incidence and delaying rhe onset of EAE. wirh 3 treatmenr doses of l0 mg/kg
bodyweight, only 3 out of l5 rats developed clinical disease, and these presented
with a delayed onset and decreased severity when compared to the control group,
which had looo/a incidence. Interestingly, | | of the I5 treated rats died for
unexplained reasons only days after their final treatments. When they died, however,
there were no EAE symptoms or spinal cord lesions present. There are no other
published studies to date that look at the use of paclitaxel in EAE animal models of
disease.
It should also be mentioned that bacteriat LPS is a potent stimulator of inflammation,
and exposure to LPS in the bloodstream can be fatal. Adverse effects of LPS toxicity
include complement activation, fever. decreased cardiac output, and ..leaky"
vasculature in the lungs causing a fluid build-up. Ultimately, damage to the heart,
lungs, and kidneys ensues, potentially leading to multiple organ failure. Interestingly,
mice that lack a functional TLR4, such as C3H/HeJ mice, are resistant to the toxic
effects of LPS (Sultzer, 1968).
Aims
Because of adverse effects of LPS toxicity, the primary aim of this chapter was to
determine whether the LPS-mimicry of paclitaxel, in combination with an enhanced
inflammatory environment as is found in EAE, was responsible for the toxicity
observed in the aforementioned study by Cao et at, (2000) in Lewis rats. Secondlv.
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this chapter sought to deternrine if'Taxol modified EAE in C57BL/6 mice using the
same dosing reginie established by Cao et ul. (2000) in rats. The dosing regime used
by Cao et ul. (200o) involved three injectiorrs given on days 6. g, and l2 after
immunising lbr the induction of EAE.
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4.2 Methods
4.2.1 Taxol preparation and administration
Taxol, a formulation of paclitaxel dissolved in ethanol and mixed into Cremophor EL
( | : | ), was diluted between S-fold and l0-fold in sterile pBS. Age- and sex-matched
animals received Taxol ( l0 mg&g or 20 mg/kg) in 500 e l injections i.p. on .specified
davs.
4.2.2 FACS staining and analysis
Cells fixed in FACS buffer (Appendix A) were labeled with FITC-conjugared anri-
B220 antibody, PE-conjugared anri-cD8 antibody, and perCp-conjugated anti-cD4
antibody (all from BD Pharmingen) to identify B cells, CD8*T cells, and CD4+ T
cells. respectively. Labeled cells were analysed on a FACScan (Chapter 2), and the
proportions of specific cell subsets were determined with CellQuest Pro software
(BD) (see Appendix C lbr gating).
4.2.3 Re-stimulation of LN cells.
Lymph nodes and spleens were removed from mice atier the treatment regimes. and
the splenocytes and LN cells were isolated as described in Chapter 2. Cells ( 106/well)
were cultured with multiple concentrations of Con A, M.tb., or MOG for 24 hr or 72
hr at 37'C. Supernatants were removed for IFN-e detection by ELISA (see Chapter
3.2.5) and replaced with fresh crcM, followed by the measurement of the
percentage of cell proliferation by the MTT assay.
4.2.4 Immunohistochemistry (IHC)
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Tis'gues, including splnal cord and ihtestine, were rernoved frorn mice and stored in
zinc fixative (Appendil A). Paraffin-embedded sections (6 em thick) were mounts-d
otr slides for IHC staining as described in Chapter z to deter,m,ine if active
proUferation had occurtsd- Sections were iucubated with a l:100 diluti.on of the
rnarker antibody, x113i'prolifer,ating cell nuclear antigen (PCNA) (blorinylated mogse
anti*vertebrate PCNA ftom PCl0 clone; BD pharmingen), and labeled eells
identified by DAB staining. AftercountEr,stainingwith methyl s*G pcisitive
staining re$ons of tissue were identified by the distinctive brorvn DAB coloratlon
under a light microscopa
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4.3 Results
4.3.1 Mice survive the maximum tolerated dose of Taxol in an inftammatorv
environment.
To determine if mice can survive treatments of raxol in an inflammatory
environment, wild-type mice or TLR4 -/- mice were immunised subcutaneously (s.c.)
in the rear flanks with cFA (200 e I tFA emursified with 500 e g/mouse M.
tuberculosis), and treated with l0 mg/kg Taxol, or the reported maximum tolerated
dose (MTD) in C57BU6 mice of 20 mg/kg of raxol (Kim er ul.,2o0l). This
immunisation procedure is typically used to induce EAE, except these particular
immunisations lacked the myelin antigen, which is obligatory for development of
EAE. The Taxol trearment regime was the same as reported by cao er a/. (2000) [i.e.
Taxol administration on days 6, 8, and l2 posrimmunisation (p.i.)1. Because
anaphylaxis and LPS toxicity are generally accompanied by laboured breathing and
hyperthermia, respectively, general appearance, body temperatures, and body
weights were monitored daily for the week of the Taxol treatments (see Chapter 2).
Overall, body temperature was minimally affected by Taxol treatments in all of the
treated groups (Fig. a. I a). Moreover, no significant weight-loss occurred in any of
the treatment groups (Fig. 4.lb). Blood serum from each group was tesred for
excessive inflammatory cytokines (IFN-e; TNF-c ), but no differences were observed
between groups (data not shown). Throughout these experiments, animals appeared
healthy, active, and well-groomed. These data suggest that Taxol does not induce
LPS-like toxic shock in wild-type mice fbllowing the treatment regime used by Cao
et al. (2OOOI
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Figure 4.1 Taxol has no effect on body temperature or weight.
wild-type (open) or TLR4 -/- (filled) mice were treated with raxol
(squares) on days 6, 8, and 12, or were left untreated (diamonds).
weight (b) and body temperature (a) were measured dairy for each
treatment group. No significant differences were seen in body
temperature or weight-loss between groups (n = 3 mice/group).
4.3.2 Taxol on days 6, 8, and 12 p.i. does not affect EAE disease development.
In the study by cao et ul. (20Q0) in rats, Taxol delayed rhe onset of EAE with
treatments given on days 6, 8, and 12 p.i. These times correspond to the peak
proliferation of peripheral myelin-reactive T cells, as well as the initial onset of
symptoms (Juedes et ul.,7oo0; Targoni et al.,zool). In the present studies in mice
using doses of l0 mg/kg and the MTD of 20 mg/kg, there was little difference
between the disease incidence, severity, or day of onset between Taxol-treated and
untreated animals (Fig. a.2 a-b). when these data were combined with a previous
experiment (n = 5) using the same treatment regime and l0 mg/kg Taxol (n =
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lO/group combined), there was still very little difference between disease onset and
severity in Taxol treated animals versus controls (Fig.4.2 c-d). Taken together, these
data suggest that Taxol is ineffective at altering EAE symptoms and progression in
C57BU6 mice using this treatment regime.
To identify differences in lesions present within the spinal cord of the animals treated
above, histological analysis was performed using hematoxylin and eosin (H&E) stain
on fixed tissue f'rom animals harvested on day 20 p.i. (Fig. a.3 a. c, & e). In H&E
stained sections, lesions were seen as a dense accumulation of purple-stained
intlammatory cell nuclei. The total number of lesions were determined for each
spinal cord and individually given a score based on the size of the foci. To ensure
that subjective scoring was equally applied to all spinal cords, the disease scores
from each animal were not compared to the slide scores until after the slide scoring
was completed. As typically seen in EAE animals. lesions were closely associated
with disease severity 
- 
i.e., spinal cords with the most lesion scores of 2 or 3 came
from the mice with the highest disease scores 
- 
regardless of whether or not they
received raxol (Fig.4.3 a&c). Exceptions, however, were inflammatory foci from
animals in remission, which had fewer and milder inflammarory fbci. Although the
scores remained elevated in these remitting mice, it is likely that the damage incurred
during the active disease was perrnanent, and further recovery is limited. Animals
that did not show symptoms of EAE also did not have lesions in their spinal cord
(Fig. 4.3 e)- The total number of inflammatory foci in the Taxol treated group (34.8 +
I I .6) and untreated group (55.4 t 16.0) were not significantly ditferenr from one
another (Student's r-test; n = 5 for both groups).
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Figure 4.2 Taxol on days 6n 8, and 12 is ineffectlve at altering
EAE. Mice treated with Taxol at 10 mg/kg (dashed line; filled squares)
or 20 mg/kg (dotted line; open squares) on days 6, 8, and 12 p.i.
showed similar incidence (a c) and severity (b, d) of EAE when
compared to a control group (filled line; open triangles). n=5 (a-b)i
n=10 including the 5 animals of 4.2 ab (c-d).
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Ts see if Broliferati'sn had occured in the cellular infiltratee, IHC was perfornred on
serially cut sections to label proliferati.ng cells in S-phase in or near the lesions in the
spinal cords. In these serially cut sections on which anti-PCNA IHC was performed,
th€fe was no evidence of proliferation within any of the lesions present in the spinal
cordsfrorn Taxol treated and untreat€d animals (Fig. rt.3 b&d, respectively). A
portion of the intestine was used as a positive control for pCNA staining and, as
expected, the ent€rocy-tes showed positive staining in the crypts, thus eonfirming that
the cellular infiltrates were not proliferating within the spinal cord 20 days after
immunisation, regardless of keatrnent status.
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Flgure tl.8 EAE splnal cord lesions.
Lesions are seen as a dense accumulation of H&E stained eells in regions of myelin
darn'age. TWo representative lesion sites are circled, b-ut other. areas of lesions exist
in the photornierographs, The spinal cords of mice with EAE were stained with H&E
(a and e), or anti'PCNA uslng IHC (b and d). A portion of an intestine was used as a
positive controlfor anti-PCNA staining (e); brswn stainirrg lndioates the presence of
PCNA, hence only the crypts, where proliferating enteroctrrtes are expected to occur,
are saining positir,€. No signifieant differences between the total number and
severity of inflamrnatory fociwere seen between Taxol'treated groups (a) and
untreated groups (c) with EAE. ln addition, the spinaleord infiltrates w€re not
proliferating in any group at,the time the tissue was harvested (day 20 p.i.). shown
here are represenhtive pictures taken from l,mouse/per group. Both miee shown
were at peak disease (4.0 +) when tissues were harvested. Photographs were tqken
at xl 00 rnagnification,
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4.3.3 Lymphocyte profiles are unaffected by Taxol treatments.
In order to determine if selective depletion of specific cell populations in the lymph
nodes was occurring tbllowing Taxol treatments, FACS analyses (see Appendix C)
were performed on DLN cells isolated from the animals treated in the above
investigations (Chapter 4.3.1 and 4.3.2) 20 days afier the initial immunisations. In
addition, two groups of mice immunised for EAE were included, a Taxol-treated and
an untreated group. Lymph node cells were isolated and pooled within individual
treatment groups. Because of pooling, the total number of LN cells from each
treatment group was not known. Specific cell populations, including CD4* T cells,
CD8* T cells. and B22O* B cells, were identified as a proportion of the total cells.
Within the total populations of the LN from each pooled group, the proportions of
CD4*T cells, CD8* T cells, and 8220" B cells remained largely unaffected in both
wild+ype and TLR4 -/- mice, regardless of whether or not the mice were immunised
to induce EAE or treated with Taxol (Table 4.l ), thus suggesting that Taxol does not
preferentially alter specific lymphocyte subsets when administered in vivo. Whether
or not Taxol, when administered with the current treatment regime, has an effect on
the total number of LN cells remains unclear since quantitative collection of cells
was not attempted.
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lnjection d. 6. 8. and I2
0D4+ PBS 3remophor EL paclitaxel
(10 mo/ko)
oaclitaxel
[20 mo/ko)
WT PBS
TLR4./- PBS
27 !1
32
27.5 !1.5
31
29 !7
32.5 t 3.5
23
25
WT CFA
TLR4-i. CFA
201 1
24 !0
19.5 r 3.5
23
26 !9
26r6
't6
19
WT EAE 26 27
a
E
E
Table 4.1 Lymphocyte populations after Taxol treatments.
Lymphocytes were isolated from the draining lymph nodes on day 20
p.i' wild-type (wr) or TLR4 -/- mice were immunized with pBS or
CFA. Some WT mice also received CFA+MOG (EAE). On days 6, 8,
and 12, animals received either PBS, Cremophor EL, Taxol (10
mg/kg), or Taxol (20 mg/kg) via i.p. injection. Cell population
percentages were determined by FACS analysis and shown
separately as cD4+ cells, cD8+ cells, and B22o+ cells in descending
order, respectively. Numbers without + error values indicate that the
data were from a single experiment. All other data were from 2
experiments.
CD8+ PBS Cremophor EL paclitaxel
(10 mo/ko)
paclitaxel
(20 mo/ko)
WT PBS
TLR4./- PBS
28.5 r 2.5
l0
28 t5
29
29.5 t 0.5
28.5 !2.5
27
29
yVT CFA
rLR4-i- CFA
18.5 t 2.5
19.5 t 1 .5
17.5 !2.5
20
2't 15
21 t6
16
18
,VT EAE 21 19
B,220+ PBS 0remoohor EL paclitaxel
(10 mo/kq)
paclitaxel
(20 mo/ko)
WT PBS
rLR4./. PBS
32.5 t 't.5
26
36.5 t 4.5
34
32.5 r 6.5
301 1
40
37
WT CFA
TLR4-/. CFA
55.5 r 3.5
50.5 t 1.5
5818
40
48 i 15
46.5 r 11.5
31
34
WT EAE 46 44
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4.3.4 Re-stimulation of lymphocytes ex vivo causes inconsistent inflammation.
Although lymphocyte populations were relarively unaffected by the Taxol
treatments, the proliferative or effector capacity of these lymphocytes may have been
impaired. To test this, LN cell.s from mice that had undergone cFA or pBS
immunisations and the above treatments (Chapter 4.3.1 and 4.3.2) were re-stimulated
with either M.tb. or con A 20 days p.i. Levels of IFN-e and proliferation were
determined for each group and compared. Three experiments were carried out, and
the first and third experiments showed enhanced tFN-e production in cultures of LN
cells fiom Taxol-treated wT animals; whereas. the second experiment showed
decreased IFN-e production in all groups. Initial results showed that the LN cells
from Taxol-treated wT mice produced higher levels of tFN-e in response to M.th.
(Fig. 4.a a) compared to TLR4 -/- mice (Fig. 4.4 b), suggesting rhar Taxol enhances
inflammation by a TlR4-dependent mechanism. A third experiment of a similap.
design, using LN cells f'rom wr animals treated with l0 mg/kg or 20 mg/kg Taxol.
also responded to M.th. re-stimulations with enhanced IFN-e production (data not
shown), lending support to the first experimental results. The second repeat of this
experiment, however, failed to produce the same results. In this second experiment.
the LN cells from Taxol-treated animals (WT and TLR4 -/-) pro<luced lower levels of
IFN-g in response to M.tb. (Fig. 4.4 c-d) compared to the CFA-immunised/untreated
controls. A similar result was obtained when these same LN cells from this second
experiment were stimulated with con A (Fig.4.4 e-0. Moreover, a MTT assay
performed on the cells from this second experiment showed that extensive
proliferation occurred and to a simileu level in all groups in response to Con A (Fig.
4.4 g-h), indicating that the lack of IFN-c production was not due to an inhibition of
proliferation. Taken together. the data obtained from the second experiment suggest
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that Taxol intefferes wi.th [FN-e productionin an unknown, TlR4-independent
manner. Because of the pooled samples and timing of LN removal in all three
experirnents, it is not clear if the observed differences were related to the Taxol
tr€afiien'ts stage o-,f, immune r€s:ponse to the immunisation, or oimply experinlental
variation. To clarify thiS, the experimerrtal design would have to be modified to
elim inate these variables.
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Figure4.4 Lymphocyte re-stimulations.
Draining lymph node cells were isolated from WT (a, c, d, and e) and
TLR4 -/- (b, d, f, and g) mice that had been immunised with CFA
(triangles) or nothing (all other shapes), and were then treated with pBS
(open shapes), or Taxol (filled shapes) on days 6, g, and 12 p.i. Cells
were cultured for 72 hr with M.tb. (a-d) or Con A (e-h). Supernatants were
removed for IFN-s detection (a-f), or assayed for proliferation by MTT (g-
h). Three experiments were performed. Results from Exp 1 are presented
in panels a-b. Exp 2 results are given in paners c-h. Results from Exp 3
(data not presented) were similar to Exp 1. panels e & f show that con A-
stimulated cells respond similarly to the M.tb.-stimulated cells from c & d.
The MTT assay (g-h) shows that the lack of rFN-s production (e-f) was
not due to inhibition ol proliferation.
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4.3.5 A single injection of Taxol has no impact on LN cell, splenocyte, or
intestinal cell proliferation in vivo.
A previous study found that Taxol (l5-30 mg/kg) adminisrered in vito inhibits
proliferation in Con A-stimulated splenocytes and purified CD4* T cells er viun after
24 hr (Mullins et al..1998b). In the present study, to determine the recovery time of
lymphocytes after a single treatment of raxol, splenocytes and LN ceils were
isolated I or 6 days after a single injection of raxol (20 mg/kg), followed by con A
re-stimulation e-tr t,ivo for 24 or 72 hr. The 72-hr culture was performed to ensure that
cells have had the full opportunity to proliferate, since 24 hr might not have been
enough time for sufficient proliferation to occur. In contrast to the previous report
(Muf lins et al., 1998b), there was little to no difference between the prolif'erative
capacity of either splenocytes or LN cells from Taxol-treated animals compared to
untreated animals at any time following the initial injection (Fig. 4.5). The 24-hr
cultures (Fig. 4.5 a-b) are expressed as a percentage of the unstimulated control to
show that cells do, in fact, proliferate in response to Con A within this short time
period, despite the earlier Taxol treatment. Because unstimulated splenocytes and LN
cells do not survive very long in culture, data from cells stimulated for 72 hr (Fig. 4.5
c-d) are shown as raw absorbance values, rather than a percentage of the
unstimulated controls. Although there does appear to be slight differences in the
degree of prolif'eration of lymph node cells after 72 hr (Fig. 4.5 c). this difference is
not signiticant with 3 eglml Con A stimulation, and is thus likely to be an artifact.
Also, this diff'erence is not consistent with the splenocyte data. nor the 24-hr lymph
node cultures. In addition, this experiment was repeated with a lower dose of Taxol
( l0 m8/kg) with similar results (data not shown). These data suggest rhar a transitory
effect of a single Taxol treatment is not present in naive T cells after 24 hr.
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Figure 4.5 A single Taxol treatment has no effect on proliferation.
Taxol (20 mg/kg)was administered to mice either 1 day (open circles) or
6 days (open squares) before removing lymph node celrs or splenocytes.
cells were cultured with three Con A concentrations for 24 hr (a&b) or 72
hr (c&d). Proliferation was determined by the MTT assay. cells from
Taxol-treated mice showed little difference in proriferation when
compared to cells from untreated mice (closed triangles). A student's f-
test showed no significant difference between Taxol-treated cells and the
untreated cells cultured with 3 eg/ml Con A.
ln a similar experiment, animals were treated with l0 mg/kg Taxol, followed by the
removal of a portion of intestine at l, 4. 7, or | 3 days after the Taxol injection. The
intestinal portions were fixed, paraffin-embedded, and mounted on slides. IHC
analysis with an anti-PCNA antibody was performed to determine if a single
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injection of Tax.ol could inhibit proliferation from consmntly dividing cells, such as
those in the intcstinal cr-Jprs. Similar to what was f,ound in LN cells and splenocytes
with a single injection of Taxol, there was no difference in intestinal celtr
proliferation between any o-f the animals tested at all tirne points (Frg. 4.6). This is
evidentby the brown *-taining in the intestinal crypts, where proliferation
constitutively @eur$, in all samples. The negative lHC-staining control sample
shows no background suining sccurred in the intestinal crypts (Fig. 4.6 0. Ttre
potency of the paclitaxel stock solution used in these experiments was oonfinned in
othel experirnents carried out at about the $ame tine, as well as $eparate experirnents
perfornred simultaneously by sthet members of this laboratory in their own studies.
It was eoncluded thereLore that either the dose of Taxsj is insuffieient to inhibit
intestinnl cell proliferEtion, or that a single dose of Taxol is not enough to inhibit
proliferation in vtvo.
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Figure 4.6 Proliferatlon occurs In intestines after single inlection of
Taxol. A single injection of Taxol (10 mg/kg) was adminlstered to mice, and
the intestines were removed following 1 'day (a), 4 days (b), 7 days (c), or 13
days (d) to identify transitory effects of Taxol. An untreated rnouse intestine
(e) was used as a positive control. The negative control (f) was obtained by
not using the anti-PCNA antibody during IHC staining. Enterocyte
proliferation occurred in all samples, evident by the brown-stained cells in the
intestinal crypts. Pictr,rres were taken under xl00 magnificatisn.
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4.4 Discussion
Taxol induces the production of inflammatory cytokines from murine macrophages
in vitrrs at concentrations above I eM. Based on the total body volume of a mouse,
these concentrations are likely to be surpassed when Taxol is injected i.p. at the
concentrations used in the experiments above; therefbre, previously reported
paclitaxel toxicity could have been an inflammatory-associated event. Although
localised Taxol concentrations in these experiments were not tested in specific
tissues (blood, fat, peritoneal cavity, etc.), human studies that looked at i.p. injections
found that a rapid uptake (within hours) and sustained bioavailability occurs when
paclitaxel is administered i.p. (Gelderbtom et a1.,2002'y. Taxol was injected into mice
that were immunised with an inflammation-causing adjuvant, CFA. In this study,
however, these animals tolerated the dosing regime chosen from a previous study in
rats by cao et al. (2000). Even ar rhe MTD, the animals appeared healthy and were
visibly and physically unaffected. To repeat previous published findings regarding
the impact of Taxol on EAE (Cao er al.,2OO0), the same dosing regime was tested in
mice receiving EAE immunisations. There was no difference in disease onset or
severity between control mice and Taxol-treated mice. Moreover. lymphocyte
profiles were very similar between the two groups one week after Taxol treatments.
There was not a consistent alteration in inf'lammation when these lymphocytes were
restimulated. Furthermore, the proliferative capacity of lymphocytes that were
isolated from Taxol-treated mice was unaffected as little as 24 hr after the Taxol
treatment. Thus, it was concluded that Taxol, with the reported treatment regimes,
does not noticeably enhance inflammation. nor does it affect EAE disease
progression in C57BU6 mice.
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The previous study by cao et al. (2000) tbund paclitaxel, delivered in a micelle
formulation, delayed the onset of EAE in Lewis rats, but the aurhors failed to
comment on the LPS-mimetic properties of paclitaxel. The fact that I l/15 animals
treated with what was determined to be the best disease-delaying concentration of
paclitaxel succumbed to an unidentified toxic effect was unfortunate, especially since
paclitaxel is a very inexpensive and readily available anti-cancer compound. In the
present study, to determine if Taxol displayed inflammatory properties in yiyo, the
drug was administered to WT mice and TLR4 -/- mice and the effects compared to
identify potential toxicities. Because paclitaxel does not induce inflammation in
TLR4 -/- murine macrophages, TLR4 -/- mice were assumed to be good controls
since no TLR4-mediated inflammation should be present. Surprisingly, different
doses of Taxol did not have any visible ef fect on either group, nor was there a
significant difference in weight or body temperature. The lack of a pyrogenic
response to Taxol in wild-type animals was particularly surprising due to the TLR4-
stimulating nature of the drug. Mice that lack TLR4 are resistant to the pyrogenic
efTects of LPS, indicating that TlR4-stimulation is crucial for hyperthermia. It is
unclear why Taxol did not induce a pyrogenic response! since both LpS and
paclitaxel stimulate TLR4 in a comparable manner.
since the MTD of raxol was shown to be.safely tolerated in c57BU6 mice
(discussed above), mice were immunised with MOG/CFA to induce EAE, and were
then treated with Taxol on days 6, 8, and lz p.i. For unknown reasons this Taxol-
dosing regime did not have the same effects in the C57BL!6 mouse model of EAE as
previously reported in a Lewis rat EAE model (cao er al., zoo0), although
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dift'erences in response between mice and rats is not unexpected, since even the
species of mouse may affect EAE induction profiles,
Macrophages in C57BL/6 mice have shown enhanced production of inflammatory
mediators 24 hr ex yivo after treatments with raxol (Mullins et al., 1998a). Here. an
attempt was made to determine if Taxol treatments enhanced the inflammatory
capacity of LN cells isolated tiom immunised, Taxol-treatedC5TBL16 mice. Initial
results suggested that there may have been a TLR4-dependent enhancement of
inflammationin M.tb.-restimulated LN cells from Taxol-treated animats; however,
this was only seen in two out of three experiments. In the second. negative
experiment, LN cells from Taxol-treated animals responded differently to the
controls, in that IFN-c levels were reduced by a TlR4-independent mechanism. This
is interesting, because in all three experiments, the DLN cells isolated from the
Taxol-treated mice were responding differently to the controls, but in dissimilar
ways. It is possible that the timing of the re-stimulations affected the outcome, since
they were performed approximately, but not exactly. one week after the final
treatment of Taxol. In addition, the LN cells tiom each treatment group were pooled,
introducing the possibility that an individual mouse skewed the results of the group.
Experimental variation cannot be ruled out either, since the immunisations in each
experiment ntay have minor differences that affect the immunopathology, including
the timing of inflammatory resotution in each experiment. while these results
suggest that paclitaxel has the ability to enhance inflammation in vivrl, care musr be
taken in interpreting these results due to the variability between mice and their in
yivo inflammatory responses to drugs.
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The increased production of IFN-e in DLN cultures from Taxol-treated WT mice. but
not TLR4 -/- mice, suggests that Taxol has affected the immune response through
LPS mimicry. This would also indicate that the eft'ects of Taxol lasted more than one
weeh since the LN cells were not harvested until one week after the last Taxol
treatment. To see if this effect of Taxol on enhanced IFN-c production was genuine,
a new experimental design would be needed, such as harvesting DLN cells 24 hr
after the last Taxol treatment, to reduce the variables mentioned above.
Re-stimulations of purified T cells with Con A have shown that Taxol exerts anti-
proliferative effects ex vivct 24 hr after injecting the mice from which the T cells were
obtained (Mullins et al.,1998b). These findings, however, are in contrast to the data
presented in Fig. 4.5. Not only was a single dose of Taxol ineffective at inhibiting
LN cellproliferation24hr later. but splenocytes were also unaffected, despite using
two different ex vivo culturing times (24 hr and 72hr).In addition, intestines were
removed from the Taxol-treated animals to see if the enterocyte prolif'eration in the
crypts was affected. Intestinal crypts are constitutively proliferating: therefore, they
are likely to be sensitive to an anti-mitotic agent like Taxol. The intestinal crypts
showed proliferation was still occurring at all time-points tested in both the control
and Taxol-treated animals. The potency of the Taxol used in these experiments was
demonstrated in Chapter 3, ruling out the possibility that the Taxol stock solution had
lost its potency. Taken together, this evidence is highly suggestive that a singte dose
of Taxol is unable to affect T cell proliferation, or proliferation of other non-immune
cells in vivo-
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One possible problem with treatments spaced over 24 hr apart, such as the treatments
performed in this study (6, 8, and l2 days), is that a prolonged time period may allow
nalve T cells to respond to the immunising antigen. The MOG/CFA emulsion creates
a subcutaneous cyst with persistent antigen exposure, providing the DLN cells with a
constant source of MOG. As shown in Fig. 4.5, naive lymphocytes were unaffected
by the anti-proliferative effects of Taxol after at least 24 hr following treatment. The
cytotoxicity of Taxol has been shown to be a function of the time to drug exposure
over a certain threshold concentration (Helson et ul., 1993). This threshold
concentration may be breached using a widely-spaced treatment regime, allowing
naive MOG-reactive T cells to become activated and proliferate during the treatment
windows between days 6 and 8, or days 8 and 12. Since clonal expansion occurs very
quickly, it is possible that in the days between Taxol reatments these expanded T
cells stop expanding, avoiding the cytotoxic effects of Taxol, and migrate into the
periphery where they can eventually become encephalogenic. It may be necessary to
close these "windows" of proliferation in order to see an effect in EAE by giving
more closely spaced injections of Taxol.
Overall, these experiments suggest that Taxol does not induce a toxic inflammatory
response in mice, which could have explained the high lethality observed by Cao at
a/. (2000) in rats. Also, the results suggest that the Taxol dosing regime performed
here, as used in the rat model by Cao et al. (2000), may not be suitable for impacting
on EAE progression in mice. Interestingly. paclitaxel is a substrate for the P-gp
efflux pump, which is known to be active in many drug-resistant cancer cells, as well
as organ-specific tissue types (Maher et a\.,2005; Richaud-Patin et a\.,2004). The P-
gp eftlux pump acts by removing selective drugs of broad substrate characteristics,
r0l
including paclitaxel, from the cell cytoplasm causing the cell to be resistant to what
is typically a lethal dose of the drug in the absence of overexpression of the pump.
Intestinal and r cells are known 0o express high levels of p-gp, on their membraoe
surfaces @liotte/ al.,Zffi4iMaher et aL, 2m5), and this multi-dmg resistance effect
might in part explain why a single dose is ineffectlve. In Chapter 3, pacliraxel was
found to be oytotoxic to proliferating splenocytes, but rhis is likely due to the
dlfferent effects of P:gp in vitro. and in vivo (Fig. 4.7). one way to circumverrt the
effeets of the Pgp pump woutrd be to inhibit the purnp with an inhibiror such as
verapamil. Another way may be to overridc the acti'on of the efrlux pump by
maintaining a higher blood concentration and a more prolonged exposure to
paelitaxel y treating mice daily for a fixed nurnber of days shortly after
imrnunisation. It is likely that TaxoN rnay- still modfy EAE disease progression in
csTBIJf mice, but thar the Taxol dosing r,egime ma.y need ts be rnodified to
optimise its effects in viva. clupter 5 confi.rms that this is indeed the case by
demonstrating a clear: effect of Taxol on EAE disease progression using a modified
treatrnent regime.
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Figure 4.7 Schematic diagram depicting the effect of P-gp efflux pump
expression on the paclitaxel concentrations surrounding cells over time in
vitro (a) and rn vivo (bl. Ambient paclitaxel concentrations remain constant
in vitroiwhereas, paclitaxel is excreted, compartmenlalised, or metabolised
in vivo, which may explain how T cells escape apoptosis in vivo after Taxol
treatments.
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Chapter 5: Effects of Anti-Mitotic Drugs on EAE
5.1 Introduction
Taxol is widely used in murine models of cancer, and while it has inflammatory
properties in vitro, there is very little evidence of these inflammatory aspects
affecting Taxol treatments in murine cancer studies. As discussed in the previous
chapter, the clear inflammatory effects of Taxol in ttitro may not be easily detectable
in live animals. The investigative approach to identify inflammation in the previous
chapter could have been modified by adjusting the time of the assays to take place
more closely to the time immediately following Taxol administrations. There is also
the possibility that there were no inflammatory effects to detect due to regulatory or
compensatory mechanisms. such as secretion of anti-inflammatory cytokines, which
could dampen down the inflammatory effects. For these reasons, Taxol still holds
promise as a treatment for EAE due to the anti-mitotic nature of the drug and limited
known side-ef'fects in viyo.
Because previous efforts to treat EAE with paclitaxel relied on markedly spaced
treatments, a tighter dosing regime may be needed to circumvent the proliferative
"windows" of the T cells. This tighter regime may also partially overcome the
possible P-gp clearance of Taxol from the T cells by mainurining a higher average
plasma concentration of the drug. When injected intravenously, Taxol has a half-life
of only 20 min in the semm of mice (Kim et ul.,zool). Evidence in humans suggests
that this half-life can be prolonged with i.p. administration of Taxol (i.v. 17.0 + I | .3
h versus i.p.28J + 8.72 h; Gelderblom et al.,2ooz), but if this is true in mice then
the relative half-life of i.p. Taxol treatments would be measured by hours, not days.
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Because Taxol is cleared quickly in mice, windows of T cell proliferation could
easily occur between treatment doses if the doses are given greater than 24 hr apart.
Therefore, by treating animals daily for 5 days, serum paclitaxel concentrations will
remain elevated for longer, allowing effective concentrations of paclitaxel to persist
in and around the proliferating T cell targets.
Peloruside, like paclitaxel, is a microtubule-stabilising compound that has similar
anti-mitotic activity to paclitaxel, but it also has a distinct, non-raxoid binding site on
tubulin (Gaitanos er al.,2oo4: Jimenez-Barbero er al., z0f],6; pineda et a1.,2004). ln
Chapter 3, it wa.s shown that peloruside did not mimic LPS in the same fashion as
Taxol and, moreover, it is reported to be less of a substrate for the p-gp efflux pump
(Gaitanos et a1.,2o04). This means that peloruside, in contrast to Taxol, may kill
proliferating cells without causing TlR4-mediated inflammarion. ln addition,
because it is less of a substrate for the P-gp pump, concentrations of peloruside may
remain elevated within cells that express P-gp mediated multi-drug resistance, such
as T cells (Richaud-Patin et a\.,2004).
Aims
The aim of the studies in this Chapter were to test whether a more intensive Taxol
treatment regime, as used in murine cancer models. can modify EAE disease
progression. Furthermore, the efficacy of peloruside. an anti-mitotic drug that lacks
the LPS mimicry of paclitaxel, would also be tested as an altemative to paclitaxel for
the treatment of EAE. Because the supply of peloruside was very limited, especially
for in vivo testing, it was expected from the outset that only a few critical in vit o
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investigations with peloruside could be attempted, and that the bulk of the
experiments in this chapter would be carried out with Taxol.
5.2 Methods
5.2.1 Drug preparations
A pre-formulation of Taxol (Bristol-Myers Squib; 100 mg/16.7 ml of
ethanol/cremophor EL) was diluted 5- l0 fold in sterile pBS before being
administered i.p. to mice at a dose of l0 mg/kg or 20 mg/kg. Purified peloruside was
dissolved in lo07o ethanol and then diluted lO-fold in pBS prior to i.p.
administration at a dose of l0 rng/kg. This dose of peloruside was chosen because
previous studies determined that l0 mg/kg was eft'ective at treating cancer in mice
(Peter Northcote; personal communication).
5.2.2 FACS analysis of DLN cells
Cells were isolated from the DLNs of C57BL/6 wild-type mice as described in
Chapter 2. These cells were then incubated with anti-CD4-PerCP, anti-CD8-PE. and
anti-CD2s-FITC antibodies to determine the percentage of these specific cell types
that were present within the DLNs. Cell events were counted using a FACS analyser,
and data were analysed using CellQuest software.
5.2.3 Assessment of in vl'uo proliferation
LN celfs and splenocytes were isolated from2D2 mice with aC57BLJ6 background,
which are transgenically modified such that the majority of CD4* T cells express a
TCR specific fbr the MOGrs-.ss peptide (Bettelli et ul.,2OO3). The isolated cells were
r06
stainpd with the eytoplasmic dye 5, Gcafrqxyfluoresoein diacetate succinimidy-l ester
(CFSE; Siema) by incubating the cells in 63 ne/ml CFSE in FBS fon I m n, fojlowed
by addition of'FCS to stop the reaction, After washng the aells in FBS, 2 X I07 sells
were han-sferred to each normal C57BU,6 rnou$e I day prior to imrnunisatisn with
MOG/CFA. Aftef 4-5 days, LN cells fromTnxol.trcated of untreated,ullce,ulere
isolated and analysed by flow cytornetry:
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5.3 Results
5.3.1 Taxol treatments of l0 mg/kg are insufficient to significantly alter EAE
progression.
Concenrations of Taxol used to treat cancer in mice vary, but l0-20 mg/kg of
bodyweight is a commonly administered dose range (Kim et al.,2OOl; Zhang and
Russell. 2006). A previous study injected l0 mg/kg Taxol i.p. daily for l0 days
without any obvious toxicity in mice (Yuan et a1.,2000), providing the basis for a
new dosing strategy in the present study. The dose of Taxol (10 mg/kg) was chosen
because of previous results in Chapter 4 that showed that l0 mg/kg of Taxol gave a
similar, if not slightly more eft'ective response than 20 mg/kg of modifying
int-lammation irt v,ivo. Taxol ( l0 mg/kg) was administered daily for 5 days to mice
pre-immunised with MOG/CFA. The 5 daily treatments were administered over one
of three time periods from days a) I -5, b) 5-9, or c) l0- l4 p.i. These time periods
were chosen because they encompass key cellular events that lead to the
development of EAE.
Disease incidence was uncharacteristically low in this particular set of animals (407o
in thecontrol group.50olo overall). Usually, S0-1007o of animals immunised develop
some form of the disease. The median day of initial onset for mice that developed
EAE from allgroups was also unusually late (day l9). Symptoms typically appear
iuound day | 2. Disease severity of the sick animals was similar among all three
groups given Taxol, as well as the untreated group. Upon close analysis of the sick
animals in each group, however, a slight difference in the timing of disease onset was
apparent (Fig. 5.l ), suggesting that. in fact, 5 daily doses of Taxol may have
impacted on EAE, delaying the development but not altering the severity of the
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disease. A more imporuant obsettvation was the fact that none of the ardmals died
frorn any sf the three treatrnent regimes, indicating ttrat toxicity is not an iswe with 5
daily injeetions of Taxol given at a dose of l0 mg/kg. Unfortunately, significant
df,fferences of onset could not be determined due to low numbers of sick corntrol
animals (u = 2),
8 10 12 14 16 1,8
Days p.i.
Figure 5.1 Effect of Taxol on mice wlth EAE.
Taxol (10 mg/kg) was administered to,mice for 5 conseeutive days
starting 'l day (red squaresi r = 3), 5 days (blue triangles; n = 4), or 10
days (green upside-down trianglee,; n = 1) following EAE immunisations,
Co rtrol animals were lmmunised, but did not reoeive Taxol (black ch'cles;
n = 2). A two-day delay of onset occurred in the sick rnice tr€ated with
Taxol. Shown, are the results from sick mice only. The original study
slarted with 5 mlce/group.
---r- Gohtrol (no tre.atment)
---r- Taxoldays 1-5
---+- Taxoldays 5-9
---+- taxoldays 10-14
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5.3.2 Taxol at its MTD delays the onset of EAE when given in multiple daily
doses.
As shown above,low doses of raxol (10 mg/kg) given daily produced a hint of a
delay of disease onset for all three regimes. To maximise the disease-delaying
potential of Taxol, the treatment doses were increased two-fold to the MTD. It was
decided that the optimal period to treat mice with the MTD of Taxol was from days
0-4 p.i. in order to fbcus primarily on the initial proliferative events that kickstart the
disease process. Treating mice with the MTD of Taxol (20 mg/kg) daily from days 0-
4 p.i. resulted in a clear delay of disease onset (Fig. 5.2). Five immunised controls
received Cremophor EL, the vehicle for paclitaxel, and showed no differences when
compared to the untreated immunised controls (data not shown).
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Figure 5.2 Taxol at 20 mg/kg delays the onset of EAE.
Mice immunised for EAE were left untreated (red; n = ZZ\ or treated with
Taxol (20 mg/kg) for 5 consecutive days (bluel r = 12) immediately
following immunisation. Shown are the average incidence (a) and
disease score (b) in the days following immunisation. Error bars on (b)
are SEM values.
n0
In immunized but non-Taxol treated animals, a slight weight loss is common in the
days that follow immunisation (up to Sc/o of body weight). Taxol-treated immunised
animals, however, exhibited a greater degree and duration of weight loss compared
to immunised control mice (Fig. 5.3). Unexpectedly, 5 out of l7 MoG-immunised,
Taxol-treated mice (29o/c) died for no apparent reason between days 7 and I I before
any symptoms of EAE were evident. Non-immunised animals receiving Taxol (20
mS/kg) daily for 5 days were alive and healthy, with negligible weight-loss, for up ro
l4 days after the initial treatment (n = 7', data not shown). These results suggest that,
firstly, paclitaxel is effective at modifying EAE disease progression; secondly. that
paclitaxel is welltolerated inC5TBL/6 mice when administered to non-immunised
animals, but an unknown toxicity occurs in mice that are both treated with paclitaxel
and immunised for EAE.
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Figure 5.3 Weight-loss from
Taxol-treatment.
Shown is the percentage of total
weight-loss from 20 mglkg Taxol-
treated (blue squares; n = 12) and
untreated (red trianglesl n = 22)
immunised mice. The greater weight-
loss in the treated group was highly
significant.
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5.3.3 Peloruside delays the onset of EAE.
Since 20 mg/kg of Taxol successfully delayed the onset of EAE, it was hypothesised
that peloruside might also have a similar effect due to its comparable microtubule-
stabilising properties. The higher solubility of peloruside in aqueous solutions allows
ill
Cremophor EL to be replaced by ethanol as the vehiele for delivery. An effective
oaRcer-treating dose of peloruside, deterrnined to be l0 mdkg (Peter Northcote;
porsonal corrmrunication), was di:ssolved in ethanoJ and adnninistercd ina lWo
solution i.p. to mice inrmunised f:or EAE. Treatments were given daily on days 0-4
p.i. similar to the Taxol treatmentr€girne given in Fig, 5.[. Peloruside delayed the
onset of E-AE and cornpletely prrevented disease in 20% of the animals reated (Fig.
5.4). Weight-loss from peloruside treatrnenls was grcater'and more prolonged
co,rnpared to the controls, but wao slightly less than the weight loss seen with Taxol
treament at 20 mg/kg. In contrastto the Taxol treatments, no deaths resulted from
peloruside in lr{O.G-immunized mice, suggesting that peloruside may be a betten
choice than Taxol for treating EAE.
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Figure 5.4 Peloruslde at 10
mg/kg delays the onset of EAE.
a-b) Peloruside (10 mg/kg; green)
delayed the onset of EAE
compared to controls (red).
Weight-loss from peloruside
,treatments are presented in (c).
Each graph is compr'ised of 2-4
experiments (n 
= 22 for control
groLlp;,h 
= 5 for peloruside treated
group). The weight loss following
peloruside treatment was highly
significant.
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53.4 Taxol treatments after diseqse onset rssult in a high incidenee of
mortality.
Treating mice with 20 ffigkgTexol daity for 5 days irnmediately after irnmunisation
resulted in a delay of disease onset (Fig. 5.3), although there was also a29Vo
mortality observed in these experiments. To see if Taxol could be used to treat
established diseasg 20 mg/kg was administered to 8 rnice daily for 5 days
inirrnediately following the first signs of diseasg wlfch normallY ocour at about l2
days p:L SurBrisingly, Taxol administered after disease onset had no signifieant
dfect on disease severity or duration (Table 5.2). Moreover, Taxol given af'ter
disease onset proved to be eventnore lethal to mice with EAE since 4 out of the 8
anirnals (SAVQ died during, or shortly,after, the first Taxol injeetion (Fig. 5.5).
Because this dosing regtme had linle irnpact on disease and resulted in a high death
rate, this pilot experimgnt was not repeated.
n4
Taxol (20 mg/kg) after disease onset
- 
Untreated control
0 2 4 6 I 10121416182022242628303234363840
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Figure 5.5 Effects of 20 mg/kg Taxol administered after disease onset.
Mice developing EAE were treated daily with 20 mg/kg Taxol for 5
consecutive days immediately after the first symptoms began to appear (blue
lines; n = 8). Untreated, immunised control mice from this experiment are
shown for comparison (red lines; n = 7). Each line represents the disease
score over time for each individual mouse in this experiment. In the Taxol-
treated group, 4 out of 8 (50%) of mice died either during, or shortly after the
Taxol treatments (thicker blue lines). Deaths in each group are represented
by a star (.).
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53,5 Compatieons between Taxol and peloruslde treatmffits
.,An'irnals treated with Taxol (FiS. 5.2) and peloruside ffig.5.4) for5,consec'uti,ve
days followi4 immunization with MOG/CFA showed similar trends in delaying the
onset and severity of disease and in causing weight-loss (Fig. 5.6), thus suggesting
that the modes of aqtion were related to a common mechanism of the two drugs'
aetiorl eithor microtubule stabilisation or their anti-mitotie actions. The delay of
onset from both drug treatments was highly s-ignificirnf cornpared to the u,ntreated
control group (Table 5.1).
There was a major differenee, however, between Trnxol and peloruside reated
animals. i{n unknown toxicity was associated with Taxol treatments, but not
peloruside treatments, adrninistersdrbefore or during EAE, as mentioqed above.
Incidentally, the deaths that oceurred frorn Taxol treatments initiated irnmediately
following immunizations (experiments of Fig. 5.2) corresponded with the initial
onset of disease in the untreated control group (Fig. 5.7). It is possible that there is a
link betw,een the known inflamrnatory effects,of Taxol in vitro (Chapter 3) and the
inflanmation associated with the onset sf EAE.
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Flgure 5.6 Overlay of Taxol, peloruslde,
and conlrol treatment results.
For comparison purposes, the results
obtained from Taxoltreatrnents (blue; Ftg.
5.2 and 5.3), peloruside treatments (green;
Fig. 5.4), and u:ntreated controls (red; Fig.
5.2,5.3, and 5.4) are combined. A similar
trend in the percentage of disease
incidence, delay of onset, and weight-loss
in drug-treated animals is evident. For
weight loss: *p<0.05, **p<O.01, and
'**p<0.001 using two-way ANOVA with a
Bonfenonf posttest comparing drug treated
animale to controls. TheFe was no
significance differenoe of weight loss
between the two drug treated Eroups.
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Deys pJ,
10 12 14
+ Taxsl (20 tngnq) dally x 5
---+- Coritrol (no treatment)
---r- Pelorusirde (10 mgftg) daily X 5
2
lr7
Incidence
2U22 (10Oo/")
9t12 (75o/")
Average day
of onset (p.i.)
Difference of means
from the control
N/A
5.0 I 1.3 daysaxol
14.4 !0.7
19.4t1.0***
19.3 t 0.9 **4t5 4.8 ! 1.7
Table 5.1 Treatments of 20 mg/kg Taxol and 10 mg/kg peloruside
significantly delay the onset of EAE.
single comparisons of the drug-treated and untreated control means were
performed in each case using student's f-test. The average day of disease
onset was calculated by averaging the first day of clinical signs for each
mouse in the group. Data are presented as the mean t SEM (** p <0.01, *** p
<0.001 compared to untreated controlgroup).
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Figure 5.7 Toxicity of Taxol corresponds to initial onset of
EAE symptoms. Taxol was toxic to 5 out of '17 mice when
administered for 5 consecutive days immediately following
immunisation for EAE. The time of toxicity corresponded to the
time when the control mice (red) began to show symptoms of
disease (dark red box) from days 7 to 12. Animals treated with
Taxol (blue) and peloruside (green) are shown for reference
(data from Fig. 5.2 and 5.4).
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Several correlations were made when the data of the peloruside treatment group, the
Taxol treatment group, and the control group were compared further (Table 5.2). The
cumulative disease score was significantly lower in Taxol and peloruside treated
groups compared to the controls. The cumulative disease score can give an indication
of disease persistence; however, the significant differences resulting from the Taxol
and peloruside treatments were primnrily due to the delay of onset. There was no
ditTerence between the treated and control groups when comparing the peak disease
scores, although Taxol-treated animals did spend significantly less time at peak
disease compared to the control group, suggesting that Taxol administered
prophylacticly may shorten the duration of disease. The average number of days
spent at peak disease for peloruside-treated etroups was not significant compared to
the control groupi however, the low sample number (n = 4) combined with the fact
that one of the mice was at peak disease score for 8 days suggests that peloruside
may actually shorten the duration of disease similar to Taxol, but this wcluld have to
be further clarified by additional experiments. Unfortunately, because of the limited
stocks of peloruside available for these experiments, it was not possible to repeat
these tests.
When Taxol was administered at the MTD for 5 consecutive days beginning at the
start of disease onset, 5OVa of the mice died. In addition, there was no significant
benefit with this therapeutic treatment regime when several disease parameters were
compared to the control group, including the level of disease severity and the
duration of disease symptoms (Table 5.2), suggesting that this treatment regime is
substantially toxic, and is not beneficial to mice displaying symptoms of EAE'
t20
freatments Controls Taxol Peloruside Taxol (upon
Jiseese omell
3umulative disease scorer
at dav 24 o.i.
26.013.0 3.3 t 3.0*' 8.5 + 3.0*', 18.1 r 2.9
Peak disease score 3.810.2 3.2 r 0.5 2.8 r 0.8 3.510.2
Days at peak diseaserr 4.9 !0.4 2.9 t 0.7... 5.0 r 1.1 3.810.9
detined here as the sum of daily disease scores
n defined here as peak score , 0.5
Table 5.2 Comparisons between different drug treatments.
Taxol (20 mg/kg) and peloruside (10 mg/kg) were given for 5 consecutive
days immediately following immunisation, except where indicated. The
cumulative disease score for each group was calculated by averaging the
sums of daily scores for each mouse following immunisation. Values are
presented as the t SEM (*. P < 0.01, *** P s 0.001; Student's t-test).
5.3.6 Spinal cord lesions correlate to disease score in Taxol- and peloruside-
treated mice.
The course of the disease in mice with ensuing EAE was significantly altered by
treating mice with Taxol or peloruside immediately after MOG-immunisation (Table
5.l ). Although no difference in pezrk disease score was fbund (Table 5.2). differences
in the number of lesions or sizes of lesions may have been present in the spinal cords
of treated mice. To test for this possibility. the spinal cord was removed at day 30 p.i.
from two representative mice from each group 
- 
one at the time of peak disease score
(i.e., 4 or greater), and one that showed no symptoms or mild symptoms of disease.
For comparison, spinal cords from a MoG-immunised, untreated mouse (disease
score of 4.5; harvested day 20 p.i.) and a normal mouse (no EAE) were also
removed. Tissues were stained with H&E to more easily identifv lesions and cellular
t2l
i,nfrltrates (Fig. 5.8). tnflamrnatory foci were counted and given a score for eaclr
slide. As typically seen in EAEmiae, the high degree of disease $ev€rif,y ensured ffrat
there would be a nunrber of lesions of all sizers. Anirnals that did n,ot ggt sick, or were
,writrdly- siek folloruing ttre Taxol or peloruside reahrcnt regin e had rto/,few
(respectively) noticeabile lesions in their spjnal coids (not shown)' Anirnals wittr a
ssvere score (i.e:, 4 or gneater) had opinal cords with multiple, but sirnilar
inflamm*tory fsei of vuying sizes (based on score) in 0re white matt€r parenchyrn4
regtudless of whether the animal was Untreared or'treated with Taxol or pelornrside.
The total nurnb,ers sf le-sions in the representative slides from each gfoup weie
eomparable, wifr the Taxol-trea-tsd animal having a-total of 67 lesions, peloruside-
treated ahimal having 60lesions, and the uutreilted aninr.al having 6l lesions. ThEse
results suggest that, onee inflamrnatory eells have e-rrtered the cNS, dlsease
progre$ses :Bs nolrflal regardless of the treauneRl
r?2
,t-tt t J:
=:r-
Figure 5.8 Spinal cords from drug-treated mice with active EAE.
Spinal cords were removed from MOG-immunised mice at peak disease
score. Mice had been treated with Taxol at 20 mg/kg (a) or peloruside at 10
mg/kg (b) for 5 consecutive days immediately following immunisation with
MOG/CFA. An immunised, non-drug treated mouse spinalcord (c), and a
normal spinal cord (d) are shown for comparison. All samples were stained
with H&E. Some typical severe lesions (i.e., score of 3) are circled for ease of
identification.
5.3.7 Re-stimulation of LN cells from Taxol and peloruside treated mice.
To see if the delay of disease onset seen following Taxol and peloruside treatrnents
was an effect of specific T cell reduction, DLN population distributions were
determined by FACS analysis from drug-treated and vehicle-treated animals 30 days
after MOG-immunisations (Fig. 5.9). Different types of T cells were considered for
comparison. The CD4" cells are considered to be the primary source of effector T
t23
eells (see review reference (El Behi et a,1.,2ffi5)). The cD8*cells have also been
shown to have a role in EAE, but generally at a later time point after tbe initial onset
of disease. The CD25* population of cellscontains T,*, sellc, which are primarily
associat€d with the recov€r)/ from EAE. Although the drug-treated percentagesof all
three LN cell populations w€re slightly lower than tho vehicle-feated controls, the
differcnces were nol significant. This suggests thatneither Taxol nor pelorriside has a
significant effeet or LN cell proliferation! or that if LN cell populations wer€
decr,eased they have recovered by day 30 p.i. when the measurements w€re taken.
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Figure 5.9 Populations of r cells from LN isolated from drug-treated
mice with EAE.
Cells were isolated from the DLNs of EAE-immunised individual mice 30
days p.i. and stained for CD4, CDB, or CDZS expression. The % of the
specific T cell subtypes in the total population of LN cells was determined by
FAcs. No significant differences were observed between the drug{reated
and vehicle-treated groups using the student's f-test. The number of
individual LN preparations for each treatment group were: peloruside (n = 5),
ethanol (n = 8), Taxol (n = 3), Cremophor (n = 5), and the control (n = 7).
The prolif'erative capacity of MOc-reactive T cells, as well as the degree of
activation, were also assessed to determine the extent, if any, of cell-specific
cytotoxicity of Taxol and peloruside. DLN cells were culturecl in media containing
Con A to induce general proliferation. or MOG to induce MOG-specific
proliferation, for 72 hr. IFN-e levels were measured in the supernatants from each
t25
group by ELISA, and proliferation was derected using rhe CyQUANT assay. The
results fiom the CyQUANT assay show that there was no proliferation in any group
in response to MOG peptide (Fig. 5.10 a). Although a memory response would
typically be present 30 days after an initial immunisation, the results presented here
are common in re-stimulation assays (30 days p.i.) with cells from EAE mice
according to Dr. Thomas Backstrom and Dr. Andrea McNeill (Malaghan Institute of
Medical Research, wellington, NZ), and Dr. Anne La Flamrne (Victoria University
of Wellington, NZ) (personal communications), possibly due to anergy. Con A,
however, did induce proliferation in each group, albeit low levels in LN cells from
untreated and peloruside treated animals, indicating that the LN cells were capable of
proliferation (Fig. 5.10 b). These results may not be reliable, however, since the
CyQUANT assay requires a low cell seeding number to maintain a linear detection
range. For Con A-stimulated or MOG-stimulated T cell proliferation to occur, the
cells must be within close proximity to APCs in the culture. which is less likely to
occur with a low seeding density. This situation was unavoidable, since the total
number of LN cells isolated from each mouse was limited, thus preventing the use of
the much preferred MTT proliferation assay.
when LN cells from each group were culrured with MoG peptide, IFN-e was
produced, but levels of this cytokine were not significantly different between groups
(Fig. 5.10 c). The con A control shows that the LN cells do produce IFN-e when
stimulated, and that the overall number of lFN-e-producing cells is not different
between groups (Fig. 5.l0 d). Although no differences were observed berween rhe
drug-treated eToups and the untreated control group, it is possible that there would
t26
have been a difference prior to day 30 in proliferative responses and antigen-specific
re-stimulation responses, but these may have been obscured at this later time point.
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Figure 5.10 Re-stimulation of LN ceils that were isolated 30 days p.i.
EAE-immunised mice were treated with Taxol (blue squaresi rt = 3),
peforuside (green circles; n = 4), or left untreated (red trianglesl r = Z) tor
5 consecutive days immediately after immunisation. DLN cells from each
mouse were isolated and cultured individually tor 72 hr in the presence of
MOG (a, c) or Con A (b, d). Proliferation was determined by the
CyQUANT assay (a-b), and IFN-< was determined by ELISA (c-d). panel
(a) shows that no proliferation occurred in response to specific-antigen
stimulation, but the cells were capable of proliferation, as shown in panel
(b). Similarly, panel (c) shows that IFN-s is produced in response to MOG;
however, the differences were not significant (based on student's t-test).
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5.3.8 Taxol does not affect CD4* T cell proliferation.
The administration of Taxol during the 5 days following MOG-immunisation delays
the onset of EAE. but does not significantly alter the lymphocyte populations or their
cytokine responses by the time disease recovery is underway. To specifically
determine if the effects of Taxol are anti-proliferative as hypothesised at the start of
this study, the effect of Taxol on in vivo proliferation was investigated. To assess
proliferation in vivo. CFSEIabeled cells were tremsfened from 2D2 mice, which are
transgenic for a majority proportion of T cells expressing a MOG-specific TCR. into
WT C57BL/6 mice. Because CFSE is a fluorescent cytoplasmic dye that is equally
divided amongst daughter cells during mitosis, the in vivo proliferation of these
MOG-specific cells could be determined by flow cytometry as a dilution of the
fluorescent label with time. One day following the transfer, mice were immunised
with MOG/CFA and immediately treated with Taxol (20 mg/kg) for 5 consecutive
days. The DLN cells were isolated one day after the final Taxol treatment and
an:rlysed for proliferation by FACS. Surprisingly, Taxol did not have any effect on
the in,tivo proliferation of the CFSE-labeled T cells (Fig. 5.1 I ), suggesting that the
detay of EAE onset in response to Taxol treatments is not due to the inhibition of
proliferation of MOG-specific T cells.
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Figure 5.11 Taxol does not affect MoG-specific T cell proliferation.
LN cells tram 2D2 mice were stained with OFSE and transferred to wild-
type mice, which were then immunised for EAE (n = 20) and treated with
20 mg/kg Taxol (n = 10), or were left untreated (n = 10). control mice (n =
6) received CFSE-labeled cells, but were not immunised for EAE and were
left untreated (data not shown). For the treated group, Taxol (20 mg/kg)
was administered daily for 5 days immediately following immunisation.
DLN cells were isolated from each mouse within these groups and
anafysed by FACS individually to detect in vivo proliferation of the cells.
The percent of total CFSE+ cells that had undergone at least one cell
division are shown (n = 10 from two separate experiments). A further
explanation of how this graph was created can be found in Appendix C.
t29
5.4 Discussion
During the course of EAE, a specific sequence of cellular events must occur for
clinical disease to develop. For example: fbllowing the initial immunisation, DCs
take up antigen and become activated, then they migrate into the DLN where they
induce MOG-reactive T cells to undergo clonal expansion. This all occurs during the
first 5 days p.i. Days 5-9 p.i. encompass what is considered to be peak prolif'eration
in the periphery (Targoni et a1.,2001). Throughout days l0-14 p.i., activated T cells
begin to migrate across the BBB where ensuing damage to the brain and spinal cord
occur (Juedes et a1.,2000; Targoni et a\.,2001), subsequently causing animals to
show symptoms of disease. Since Taxol, when adrninistered on days 6, 8. and l2 had
no effect on EAE development (Chapter 4), it was thought that by targeting these
specific 5-day periods, Taxol would then have an effect on the EAE disease course.
Although the disease incidence was low in the particular set of experiments used to
test these treatment regimes, treatments of Taxol (10 mg/kg) with all three proposed
dosing regimes caused what appeared to be a small delay in disease onset of about 2
days, suggesting that Taxol can affect EAE disease progression if the dosing regime
is optimised.
When the treatment regime was altered to 5 consecutive daily treatments with Taxol
at i$ Mm of 20 mg/kg given immediately after immunisation. there was a clear and
significant delay of disease onset, but also a29o/o mortality rate. Neither monality,
nor a significant delay of onset, was seen in animals treated with l0 mg/kg with the
same regime, but an unexpected low disease incidence may have obscured the
outcome of this experiment. Most interestingly, peloruside delayed the onset of EAE
in a manner similar to high-dose Taxol, but without causing any deaths. The
r30
mechanism that causes the delay of onset appeared to be related to microtubule-
stabilisation, or at least the anti-mitotic mechanism of the two drugs, since both drugs
had nearly identical disease modifying effects when administered at the active doses.
The subsequent weight loss, disease scores. and delay of onset of EAE in mice
treated with both Taxol and peloruside were nearly indistinguishable (Fig. 5.6).
Other disease parameters were also similar between the two treated groups, including
the cumulative disease scores and the peak disease scores (Table 5.2). n major
difference between the Taxol-treated and peloruside-treated groups is that 29o/c af the
Taxol-treated animals died between days 7-12 p.i.; whereas, peloruside was not
lethal to any of the animals. Control animals that did not receive the initial
immunisation, but did receive Taxol treatments, were largely unaffected based on
appearance and weight, and none of these control animals died. This is a strong
indication that Taxol itself is not toxic with this dosing regime, but for reasons
unknown at this time, the combination of Taxol in MOG-immunised mice proved to
be fatal in about one-third of the animals. Thus, there is some adverse interaction
between the Taxol effect and the MOG-immunisation effect in some of the animals.
Interestingly, the Taxol-induced deaths occurred between days 7 and l2 p.i., which
coincides with the normal onset of EAE in untreated, but immunised control mice
(Fig. 5.7). Additionally, mice treated with Taxol at the time of disease onset also
showed high lethality with 4 out of 8 animals dying either during or shortly after the
5-day treatment regime. Combined with the lethality observed by cao et at (2ooo)
after Taxol treatments in rats with EAE, these data suggest that there is an
inflammatory cross-reaction when Taxol is given to animals in the induction and
effector phases of EAE. especially since this toxicity is not observed in animals
l3l
treated with peloruside, which lacks the inflammatory stimulation effects. One
cannot rule out the possibility that Taxol-treatments caused the deaths in mice with
the most aggressive disease. This scenirio could potentially cause the data to be
skewed making it appear that a delay of onset had occurred. A much more extensive
investigation would be needed, however. to positively link Taxol administration with
enhanced mortality in mice and rats.
The common action of peloruside and paclitaxel is the ability to prevent microtubule
depolymerisation. The delay of EAE in response to altered microtubule function is
further supported by experiments with colchicine, a microtubule-depolymerising
drug, which similarly altered the development of EAE (Lyons et ul.,1986). As
shown previously in chapter 3. however, paclitaxel differs tiom peloruside by
causing inflammatory events to occur due to TlR4-complex stimulation. Because a
similar delay of onset was observed in mice with EAE that were treated with either
Taxol or peloruside, it can be tentatively concluded that the delay of onset is due to
microtubule stabilisation and/or its downstream effects (mitotic arrest and apoptosis),
and not because of the LPS-mimicking characteristics of Taxol.
While these results clearly indicate that microtubule-stabilising drugs delay the onset
of EAE, the mechanism responsible for this delay is not known. The most notable
and practical function of microtubule-stabilising drugs is their use in cancer
treatment. Simply put, these drugs kill rapidly dividing cancer cells. Therefore, T
cells that become activated during the initial 5 days after MOG-immunisation may
succumb to the anti-mitotic effects of both drugs, which would ultimately delay the
onset of disease until the Taxol is cleared. Once Taxol is no longer affecting T cell
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proliferation (24hr after the last treatment), the MOG-reactive T cells may begin to
successfully proliferate. eventually leading to the development of EAE, albeit later
than normal. This theory was supported by the fact that re-stimulation assays showed
that there were no differences between the treated and untreated groups regarding
both MoG-specific proliferation and IFN-e production (Fig. 5.1 l). This finding.
however, may be due to the timing of the assays (day 30 p.i.), as it is not unusual to
see a limited MOG-re-stimulated T cell response after 30 days have passed since the
initial immunisation. Assessment of responses at a time when Taxol directly exerts
its effect is required and would form the basis of future studies in this laboratory.
To more accurately determine whether Taxol was inhibiting proliferation of MOG-
reactive T cells during the induction phase of disease, transgenic T cells specific fbr
MoG peptide were stained with GFSE and transferred to mice a day prior to MoG
immunisation and the subsequent Taxol treatments for 5 consecutive days. It was
clear that during the time of the Taxol treatments, proliferation was occurring in
these CFSE-labeled cells, thus proving that Taxol did not inhibit in vit,o proliferation
of these autoreactive T cells during the induction phase of disease. This was very
surprising because low nM concentrations of paclitaxel are cytotoxic to proliferating
splenocytes in vitro (Chapter 3). It is possible that the reason cyrotoxicity did nor
occur in vivo was due to the P-gp efflux pump, which is responsible for multi-drug
resistance in multiple cancer cell lines. Although the P-gp pump is active in vitro
(Gaitanos et a1.,2004), the celts are persistently exposed to the drug when it is added
to a culture. Taxol concentrations in uil'o, on the other hand, are initially high, but
rapidly decrease over the course of hours (Kim er ul.,2ool). The p-gp pumps only
need to keep clearing Taxol from the cells for hours before the blood-Taxol
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aoncenrations are reduoed to survivable levels. This may explain why Taxol d,id not
kill the CFSE.labeled T eells in vivo: however, this abscncc of an effect on T eell
proliferation leaves the question of how Taxol and peloruside delay: &4E
unan$wered-
It was shown previously in Chapter 3 that both paclitaxel and peloruside decrease
TNF-e production in MO exposed to inflammation.inducinglPS. Blooking the
effects of TNF-e has been shown to pr€vent,an entire cascade of inflammatory
cy-tokines (Feldmann, 2002; Feldmann et al.,1995), gtving supBort to the po-ssible
imrtrunornodifyrng effects of Taxol in EAE, It has also been shown that functional
microtubules are nesessary f'or antigen processing and presentation b,y DCs and M@s
(Peachmarfl e t al.,2AA4),In thio particular study, the authors specifically identified
paelitaxel as a drarnatic reducer of antigen processing/pr,esentation in DCs due to
microtubule stabilisaticm. Beeause of the diverse roles of microtubules in cellular
functi,ons, there are many other plausible explanations for the disease-delaying
effects of Taxol; however, it is clear, based on the studies with CFSE-labeled MOG-
speeific T sells, 'that the most likely scenafio 
- 
prbventing proliferation of T cells 
-
does not occur with Taxol heatnrents.
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6.1
Chapter 6: General Discussion
Summarv
In the present study, it has been shown that the microtubule-stabilising drugs,
paclitaxel and peloruside, are capable of modifying the progression of EAE. Hence,
paclitaxel and peloruside have the potential to impact MS, but further research is
needed to optimise the disease modifying effects.
The primary hypothesis of this project was that microtubule-stabilising anti-mitotic
compounds would inhibit proliferation in the autoreactive CD4* T cells that mediate
EAE and MS. Paclitaxel, being inexpensive and readily attainable, was chosen as the
ideal microtubule-stabilising drug candidate. A novel microtubule-stabilising
compound, peloruside, was also tested as an altemative to paclitaxel to identify
immunomoditying activities, and to act as a microtubule-st:rbilising control. It was a
natural approach to initiate the present studies by showing that T cells are susceptible
to the anti-mitotic activities of both paclitaxel and peloruside in vitro. Because
peloruside is one of several cytotoxic compounds to be isolated trom the same
sponge species, including mycalamide and pateamine, these three compounds were
assessed for their direct effects on T cell proliferation and activation. Pateamine has
been found to be a protein synthesis inhibitor that blocks the function of the initiation
factor, elF4A (Bordeleau et u1.,2005). Mycalamide, like pateamine, is a protein
synthesis inhibitor but interacts directly with the ribosome (Burres and Clement,
1989). Although out of the scope of the presenr srudy, mycalamide exhibited
immunosuppressive activities that warrant further investigations. More relevant to
the present study, peloruside and paclitaxel were both cytotoxic to Con A-stimulated
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splenocytes, giving the first indication that proliferating T cells succumb to these
anti-mitotic drugs.
The initial experiments identified the effects of paclitaxel and peloruside on T cells,
but EAE lesions, although mediated by CD4* T cells, iue liugely caused by the
phagocytic activities of M@. Interestingly, paclitaxel is known to stimulate the TLR-
4 complex in murine M@ similarly to LPS, inducing the production of inflammatory
mediators. These LPS-mimicking activities of paclitaxel could have presented a
major problem in animal studies, especially since the initiating events of EAE are
largely enhanced by the TlR-stimulating effects from the CFA adjuvant. Peloruside,
on the other hand, is known to bind to a different region of tubulin from paclitaxel
(Gaitanos et a|.,2004;Jimenez-Barbero ar a1,,2006: Pineda et a\.,2004). Since both
peloruside and paclitaxel have a similar mode of action, these drugs were assessed
for inflammatory-inducing activities in BMMO. Unlike paclitaxel, peloruside did not
induce BMMO production of inflammatory cytokines. This finding was not
surprising because of the distinct microtubule-binding characteristics. Other studies
have found that the TlR4-stimulating effects of paclitaxel are unique to this drug
(Kirikae et al.,1996: Ojima et al.,2OO3), and that other microtubule-stabilising
compounds without LPS-mimicking effects could also potentially serve as alternative
microtubule-stabilising compounds ro paclitaxel (Muhlradt and Sasse, lggT). Many
of these other compounds. however, are expensive and not easy to source, especially
in the quantities needed for in vivo studies.
The inflammation-causing properties of paclitaxel were an ongoing concern. Because
EAE immunisations produce an inflammatory environment, it was important to
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identify any synergistic inflammatory effects from a combination of paclitaxel and
LPS. Both paclitaxel and peloruside were cultured with BMMO in the presence of
LPS, and surprisingly. both compounds decreased the production of a key
inflammatory mediator TNF-e, as well as NO. It is not known why paclitaxel
displays these paradoxical et'fects of causing the release of inflammatory cytokines.
yet preventing their production in BMM@ in the presence of LPS. Although the
mechanism behind these anti-inflammatory responses is yet to be resolved, these
results showed that peloruside and paclitaxel may actually reduce inflammation, as
well as exhibiting anti-mitotic functions. The significance of this finding is highly
valuable in the context of treating an inflammatory autoimmune disease, such as
EAE.
A previous study by Cao et zll. (2000) found that Taxol delayed the onset of EAE in
actively immunised Lewis rats. The authors observed that the most effective Taxol
treatment regime for delaying onset unfortunately also caused the deaths of I I out of
l5 rats. Afterfurtherreview of this study, the observations made by these authors
lead me to speculate that the TlR4-complex-stimulating function of Taxol may have
contributed to the lethality in these rats by enhancing the production of inflammatory
cytokines in an environment where severe inflammation already exists. Attempts
were made to repeat these experiments in C57BU6 mice, and to identify any
inflammatory eff'ects of Taxol in vivo. The treatment regime borrowed from Cao er
a/. (2000) involved i.p. injections of Taxol at concentrations as high as the MTD on
days 6. 8, and | 2 following MOG-immunisation. Although the mice tolerate these
doses well, these treatments did not modify EAE disease progression. There may be
many reasons why there was no disease-altering effect, including such possibilities
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as higlt P-gp efflux pump expression on T cells, differences in EAE progression and
Taxol clearance rates in rats versus mice, or autoimmune cell proliferative
"windows" occurring in the 2 and 4 day periods between Taxol treatments in mice.
The activity of the P-gp efflux pump was not specifically tested, but methods could
be employed to identify this activity such as the use of rhodamine 123 in
colourimetric assays. Despite attempts to rule out the use of Taxol as a potential
therapeutic for EAE, these studies did not provide sufficient evidence to suggest that
this drug has adverse efTects in mice due to its LPS-mimicking activity. At this point
in the project it was decided that Taxol would continue to be the drug of choice to
optimise in order to modify EAE, since the evidence tiom Chapter 4 suggests that
TLR4-stimulating activity would not be a major factor.
Based on the evidence from Chapter 4, it was determined that disease-modifying
effects of paclitaxel as seen in Lewis rats (Cao et a\.,2000) did not occur with the
same treatment regime when administered to mice. As mentioned earlier, there are
several possibilities that may explain why no effect on disease was seen. To
overcome these possibilities, a new treatment regime was proposed, which involved
daily administrations of Taxol during the time periods encompassing key cellular
events in the initiation of EAE. Initial attempts to modify the onset of EAE with a
new Taxol regime were hampered by low EAE incidence in the groups. Other factors
also could have contributed to the limited response, including the quantity of Taxol
administered to each mouse. To exclude this possibility from affecting further
experiments, Taxol doses were lifted to the MTD. In addition, administrations of
Taxol were focused on the initial days immediately after MOG-immunisation, with
the thought that it could directly target the initial proliferation of MOG-reactive T
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cells. When these experiments were performed, a significamt delay of onset occurred,
altltough there was concomitant cytotoxicity. This experiment confirmed what Cao et
a/. (2000) found in rats with paclitaxel. and now raises a few questions: can all
microtubule stabilising compounds affect EAE development? [f so, what is the
mechanism?
Peloruside, our alternative microtubule-stabilising drug to paclitaxel, also
successfully delayed the onset of EAE in mice when administered with the same
regime as the disease-delaying doses of paclitaxel. Moreover. the Taxol-related
toxicity did not occur with peloruside treatments. This peloruside-induced delay of
onset is highly important, as it suggests that the disease-modifying effects of both
Taxol and peloruside are related to their primary mode of action 
- 
the disruption of
normal microtubular function. The primary hypothesis of this project was that
microtubule-stabilisation causes proliferating cells to apoptose, thus inducing cell
death in the effector cD4+ T cells that mediate EAE. This, however, was not rhe
case, since autoreactive CD4" T cells continued to proliferate in vivo after the
administration of disease-modifying Taxol treatments. Limitations of peloruside
supply prevented further experimentation in vivrr, so it remains to be seen if
peloruside also has no effect on T cell proliferation in vivo. Although the exact
mechanism of disease modification remains unanswered, the known microtubule-
stabilising functions of both compounds are likely to be the root cause.
It is important to mention that a micellar formulation of paclitaxel was used in phase
II clinical trials to treat MS (Angiotech_Pharmaceuticals, 2002). The results of these
trials showed no significant effects between 174 paclitaxel-treated and placebo-
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treated subjects. In these studies. patients with secondary-progressive MS were
treated with paclitaxel once every 4 weeks for 6 months. This is a confusing
approach, since the cytotoxic effects of paclitaxelare a result of exposure time to the
drug over a threshold concentration (Helson et ul.,1993). When these trials began,
the research by Cao er al. (2000) was the only published animal study identifying
possible immunomodifying effects in a MS-like disease. As I have shown here,
Taxol should not be dismissed as a failed MS therapy. This example simply
highlights the fact that further EAE animal studies are critical to determine the
mechanism behind the modification of disease in order to devise a better treatment
strategy for MS patients.
6.2 Future Directions
While peloruside served as a control throughout this project, it is important to
consider that peloruside is in limited supply and was only administered to 5 mice in
total. The amount of peloruside used in these experiments was l/10'h of the world's
known supply of peloruside at the time these experiments were performed. When
peloruside supplies are not as precions. further studies c:rn be undertaken to develop
this drug as a potential treatment for MS.
There are many roles for microtubules during normal cell function, and different
cells utilise microtubules for various reasons. In DC. for example, the microtubule-
stabilising drug docetaxel has been shown to alter chemotactic motility (Nakashima
et a1.,2005), which would have major implications during the initial T cell priming
events of EAE. Another study has shown that normal microtubule functions are
required for antigen presentation and processing in DC and M@, and paclitaxel was
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shown to alter antigen presentation in these cells (Peachman et c/., 2004). The
current project focused on T cells. but it is clear that other immune cells may have
had impaired functions from Taxol and peloruside treatments. Introducing confocal
microscopic detection methods, including total internal reflection fluorescence
(TIRF), could help determine other immune cell responses to Taxol and peloruside,
such as an impaired secretory pathway or altered migratory capacity.
The dosing regime of Taxol and peloruside that delayed the onset of EAE, although
successful, was not fully optimised. As mentioned in Chapter 5, there were several
different time periods that could be targeted in order to maxinri.se the disease-
modifying effects. In addition, the dose of Taxol used in the disease modifying
experiments was pushed to its limits in order to reduce the possibility that the
quantities of drug given to mice were too low to see an etfect. [n fact. less Taxol may
still modify disease, and it might also reduce toxicity. In addition, there is no reason
why daily drug administrations cannot be extended for periods longer than 5
consecutive days, so long as weight-loss and toxicity do not become an issue. Taken
together, the treatment regime can be modified fbr optimal disease-modifying results
without the adverse side-effec[s.
The EAE model used throughout this project was the C57BU6 model of disease.
This particula' model of EAE is useful to establish an early intervention during the
initial phases of disease; however, most MS patients do not know they will get the
disease until they have had it for some time. At that point, it is too late tbr early
intervention. Different EAE animal models. such as the relapsing-remitting SJL
mouse model. may be more appropriate for testing a potential therapy for the most
t4l
common MS phenotype, relapsing-remitting disease. There are many more animal
models of EAE that have characteristics more closely related to certain MS sub-
types. Exploring the effects of microtubule-stabilising drugs in other EAE animal
models may be a more effective way to establish a crossover link to a MS therapy.
An interesting, and unexpected effect from the Taxol treatments was the toxicity that
accompanied the onset of EAE. This detrimental interaction may have a broader
importance regarding the treatment of patients with Taxol when presenting with
general inflammation. Although the TLR4-stimulating activities of paclitaxel are
limited to murine animals, paclitaxel and other taxane derivatives have been linked to
the production of another inflammatory mediator, COX-2, in human monocytes
(Cassidy et u|.,2002). Repeating the Taxol treatment regime in MOG-immunised
TLR4 -/- mice may elucidate the mechanism by which the toxicity occurs, thus
ruling out contraindications for Taxol treatments in humans.
Taxol is a widely used drug with the potential to rreat MS. and peloruside, also
having potential as a MS treatment, is being isolated in increasing quantities each
year. Taxol, as shown here, has its drawbacks. But it is only a matter of time before
peloruside will become widely available, which would allow further studies to take
place in the EAE animal model of disease. Hopefully, the project presented here
gives insight into using anti-mitotic drugs as treatments for CD4+ T celt-mediated
autoimmune disorders, which may lead to another treatment option for MS patients
around the world.
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Appendix A: Buffers and Reagents
ee[ Wash
Dulbeccs' s Modified Eagle lvledium containing:
- lolo pen sarep (100 U penicillin/ml and l00eg streptomycin/ml)
- 30 rnM HEPES
CTCM
Dulbescoi s Mbdified Eagle Mediurn eontainin g:
- lQTo Foetal Calf Serum (FCS)
- l% pen-strep (I00 U penicillin/ml and l00eg streptornycirflml)
- 1 mM L.glutamine
- l0 mM IilEPES
= 5.5 pM e:=niercaptoethanol
ELISA Capturo Buffer (I['Nq IInl?, and IL-10)
- 0.1M NazHPO+
- ddHzO
pH to9.0
ELISA Capture Buffer (TI{['-a)
- 0.1 M NazHPO+
- ddHeO
pH to6.0
r6l
ELISA Derreloprnent.$toppiqg Reagent
- CI.18 M HzSO+
- ddHzo
FACS Buffer
- A.lEo sodiurn azide
- 2% t@tal ealf,$erum
- P,BS
MTT Solution
- sterile l0rnlvtdPBs
- 5 mg/nnl MTT (Sigma)
MTT Soluhlliser (500 ml)
- rcqo (50 $ sodium dodeeyl sulfate (SDS)
- 45.s/o (225 mI) dimethylforrnamide (DMD
pH 4.5 witb acetic acid
Diluted to 500 ml withddHao
PBS
Stedle ddHzg eontainin :
. NaTHPO+ 8.7 mM
- NaH2Pn- 1..3 mM
- NaC,l 145 mM
162
pH 7.4
Pertuesis Toxin Buffer
Sterile ddHzO containing:
- Tris-Cl
- NaCl
- Tris Base
- lN HCL
15 rnM
0.5 M
12.1 g
I1.5 nrl
- Triton X-100 0.0l7Vo
TPBS
- PBS containing 0.,A5Vo Tween-20
Tris Buffer (0.1 M; l Litre)
- Distilled woter 900 ml
pH ro 7.4
Zinc Fixative(l Lttre)
- Calciunr Acetate 0.5 g
- Znc Asetate 5 g
- Zinc Chloride, 5 g
- 0.1 M Tris Bu,ffer t L
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Appendix B: Determining peloruside purity
Peloruside is a novel compound with a very limited supply. The purity of peloruside
was questioned when it was observed in our lab that non-proliferating MO died when
cultured with peloruside, which is known to be cytotoxic to proliferating cells only.
Because of this. there are potential issues regarding the purity of the peloruside used
in the present experiment. Using nuclear magnetic resonance (NMR), the purity of
peloruside was determined by the Natural Products Group t'rom the School of
Chemical and Physical Sciences, Victoria University of Wellington. There were two
stocks of peloruside that were used throughout this thesis - an older batch with
uncertain purity, and a newer, purer batch as determined by NMR spectra. These two
batches were tested side-by-side in BMM@ and Con-A stimulated splenocytes to
investigate possible cytotoxic contaminants. The newer batch of peloruside had little
effect on non-proliferating BMMO as determined by the MTT assay after t72hr
culture (Panel a). The older batch of peloruside completely abolished metabolic
activity at concentrations as low as 3l nM under the same culture conditions. With
concentrations at or above 3l nM, blebbing and shriveling of BMM@, induced by the
older batch of peloruside, was evident within hours, and clearly visible under a light
microscope (no pictures available). Both Con-A stimulated (Panel b) and
unstimulated splenocytes (Panel c) were susceptible to the cytotoxicity of the older
peloruside at similar concentrations; whereas, the newer peloruside was only
cytotoxic to proliferating splenocytes (Panel b), albeit only partially in this
experiment. This set of experiments was performed once to quickly verify the quality
of the peloruside. Unless it is specifically stated, all work with peloruside was
performed using the newer batch.
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Testing the r€lative purity of a newer batch vs. an older
batch of peloruside. The older batch of peloruside (open circles)
strongly inhibfted BMMO metabolism (a} and was cytotoxic to
stimulated splenocytes (b) and unstimulated splenocytes (c). The
newer peloruside (fitled circles) had little or no effect in BMM@ (a)
and unstimulated splenocytes (c). Mild cytotoxicity was observed
in stimulated splenocytes (b). Tests were performed once in
tripficate. Results are expressed as ao/o of an untreated control.
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Appendix C: FACS Gating
Annexin/Pl staining
a.
o4-o2-12029
stz9
o4.t2,12026
ro0 rdl d2 t63 r6a
COlqt0
Determining T cell apoptosis by FAGS
Splenocytes were cultured with anti-CD3 and cytotoxic agents (Chapter
3.3.1) tor 24 or 72hr. Cells were stained with markers for CD4+ or CD8+ T
cells, and Annexin V/Pl. The sample represented above (Panels a-d) is from
a24-hr culture containing pateamine at concentrations slightly above the lCso
value. and is stained with Annexin V/Pl and a CD4+ marker. The emission
spectrum of Pl encompasses the FL-2 and FL-3 fluorescent channels,
causing Pl-stained events to appear in the same detection channel as the
CD4+ and CD8+ labels (FL-3), which are easily discernable based on the
levelof fluorescence (Panelb). Back-gating in Panel (b) determined where to
set the gates lor R2 in Panel (a), which excludes non-cellular events and
debris. Panels (b) & (c) show events that occur within R2 from Panel (a). The
% of CD4+ or CD8+ non-apoptotic cells was determined by placing a gate
(R1) around the Annexin V/Pl negative cells and CD4+ or CD8+ cells (Panel
c). The number of events in R1 in the representative sample above is 9.81
(Panel d; under the "% Gated" in R1). This number was determined for all
samples, including a control sample from the drug-free culture. To determine
the comparative percentages of non-apoptotic cells, the "7o Gated" value_for
R1 in each sample was divided by the "7" Gated" R1 value from the drug-
free control.
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ldentifying percentages of lymphocyte sub-populations from LN cells.
Cells lsolated from LN were labeled with marker antibodies and analysed
by FACS. Shown above is a representative sample of the LN cell
population identification process. Panel (a) shows the gate (black line
around the accumulation of events) placed around the region in which the
vast majority of lymphocytes are detected. Panels (b & c) show the events
that occur after the gating in Panel (a). Quadrants settings were
determined in a sample stained with fluorescently-labeled control lgG
antibodies to compensate for autofluorescence (b). Panel (c) shows the
distinct lymphocyte sub-populations within the previously set quadrant from
(a). The statistics obtained from this sample are shown in Panel (d), where
the lymphocyte sub-populations were calculated based on the ""/o G;ted';
for the specific cell sub-type in each quadrant. Lymphocyte populations
from each sample were averaged, and were represented in each
experiment as + SEM.
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Identifying proliferation in CD4* T cells from CFSE-labeled 2D2 cells
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Determining the extent of rn vivo proliferation of CFSE-labeled cells from
2D2 mice.
Splenocyte and LN cells from 2D2 mice, which are transgenic to have over 80%
of CD4+ T cells expressing MOG-specific TCR, were transferred to wild-type
C57BL/6 mice. These animals were MOG-immunised and either treated with
Taxol, or left untreated. The above sample (Panels a & b) represents a typical
FACS plot from this set of experiments. Two other control groups were included:
1) a non-immunised/untreated group that received CFSE labeled cells (Panel c),
and 2) a non-immunised/untreated group that did not receive CFSE-labeled cells
(Panel d). After 4-5 days p.i., the DLN cells were removed from each group and
labeled with a CD4+ fluorescent marker. The gate in Panel (a) (R1) surrounds a
dense region of events that contained the majority of CD4 and CFSE double-
positive events, as determined by back-gating. To determine the % of proliferating
CD4+CFSE+ cells, the R2 gate was placed around ALL of the CD4+CFSE+ cells,
and the R3 gate was placed around only the CD4+CFSE+ cells that have
undergone one cell division, as determined by the shift in fluorescence (Panel b).
The R3 value was divided by the R2 value (Panel e) in order to calculate % of
proliferating MOG-specific CD4+ cells. Panel (c) shows the position of non-
proliferating CD4+CFSE+ cells from non-immunised mice that received CFSE-
labeled cells, and Panel (d) shows the position of cells from a normal control
mouse.
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